Method for decreasing inflammation and stress in a mammal

Information

  • Patent Grant
  • 9415083
  • Patent Number
    9,415,083
  • Date Filed
    Friday, February 1, 2008
    16 years ago
  • Date Issued
    Tuesday, August 16, 2016
    8 years ago
Abstract
A method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.
Description
FIELD OF THE INVENTION

The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.


BACKGROUND OF THE INVENTION

Studies have indicated that restriction of caloric intake by food deprivation slows down certain undesirable cellular processes in laboratory animals, many associated with aging and age-related diseases.


C-reactive protein (abbreviated as CRP) is one kind of acute phase protein, and although its blood level rapidly increases on inflammatory diseases or the like accompanying the disorganization, it is present in healthy mammal blood.


The inflammatory response plays an important role in the onset, development and evolution of stress, cardiac ischemia, and arthritic changes. Elevated serum levels of C-reactive protein (CRP) are non-specific but sensitive markers of the acute inflammatory response. C-reactive protein is an acute phase reactant protein. However, C-reactive protein levels can increase up to 100 or even 500 times during acute inflammation. This staggering response is mainly regulated by proinflammatory cytokines, in particular interleukin-6, and is largely unaffected by anti-inflammatory drugs and hormones. This suggests that the proinflammatory effects of C-reactive protein may contribute to the adverse outcome associated with higher levels of this acute phase reactant protein.


Additionally, due to its ligand binding properties, C-reactive protein plays a part in the innate immunity (opsonization) and in the removal of membrane and nuclear material from necrotic cells. C-reactive protein can also bind to complement factor Clq and factor H and activate the classic pathway of complement activation. C-reactive protein is present in atherosclerotic plaques but not in the normal vessel wall where often co-localize with the terminal complement complex. C-reactive protein can also induce tissue factor expression by monocytes.


There still exists a need for a method for decreasing inflammation and stress in a mammal resulting in enhancement of quality of life of a mammal, increase the length of the lifespan of a mammal, and providing for a healthier mammal.


It is therefore an object of the present invention to provide a method for decreasing inflammation and stress in a mammal including a human and/or a companion animal comprising; administration to a mammal a composition comprising a glucose anti-metabolite, avocado, avocado extract or mannoheptulose; and wherein the composition comprises amounts of the glucose anti-metabolite, avocado extract, avocado or mannoheptulose sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite, avocado extract, avocado or mannoheptulose.


SUMMARY OF THE INVENTION

The present invention is directed to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein the composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.


The present invention further relates to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising an avocado; and wherein the composition comprises amounts of the avocado sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado.


The present invention further relates to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising an avocado extract; and wherein the composition comprises amounts of the avocado extract sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado extract.


The present invention further relates to a method for decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising mannoheptulose; and wherein the composition comprises amounts of the mannoheptulose sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the mannoheptulose.







DETAILED DESCRIPTION OF THE INVENTION

The method for the present invention comprises decreasing inflammation and stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein the composition comprises amounts of the glucose anti-metabolite sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite.


These and other limitations of the compositions and methods of the present invention, as well as many of the optional ingredients suitable for use herein, are described in detail hereinafter.


As used herein, the term “adapted for use” means that the composition described can meet the American Association of Feed Control Officials (AAFCO) safety requirements for providing animal food products for an animal as may be amended from time to time.


As used herein, the term “companion animal” means an animal preferably including (for example) dogs, cats, kitten, puppy, senior dog, senior cat, adult dog, adult cat, horses, cows, pigs, rabbits, guinea pig, hamster, gerbil, ferret, horses, zoo mammals, fish, birds and the like. Dogs, cats, kitten, puppy, senior dog, senior cat, adult dog, adult cat are particularly preferred.


As used herein, the term “composition” means a composition that can be administered to a human that is orally ingested by the human, bars, pills, capsules, administered to companion animal that is orally ingested by a companion animal, supplements for a companion animal, pet food, dog food, cat food, treats, biscuits, raw hide, treats, chews, fillers, gravy, sauce, beverage, supplemental water, and combinations thereof. The composition can be wet, moist, and/or dry.


The term “complete and nutritionally balanced” as used herein, unless otherwise specified, refers to a composition having all known required nutrients in proper amounts and proportions based upon the recommendation of recognized authorities in the field of animal nutrition.


As used herein, the term “mammal” includes humans and/or companion animals.


All percentages, parts and ratios as used herein are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.


The composition and methods of the present invention can comprise, consist of, or consist essentially of, the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in compositions intended for mammal consumption.


Method


The present invention is a method for decreasing inflammation and stress in a mammal. The method comprises administration to a mammal a composition comprising a glucose anti-metabolite or a avocado or mannoheptulose or avocado extract; and wherein the composition comprises amounts of the glucose anti-metabolite or avocado or avocado extract or mannoheptulose sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the glucose anti-metabolite or a avocado or avocado extract or mannoheptulose.


Composition Form


The compositions are adapted for use by mammals. The composition of the present invention is preferably administered to decreasing inflammation and stress by lowering the level of C-reactive protein in the blood of a mammal. The composition of the present invention can be a moist composition (i.e. those having a total moisture content of from about 16% to 50%, by weight of the product), and/or a wet composition (i.e. those having a total moisture content of greater than 50%, by weight of the product), and/or dry composition (i.e. those having a total moisture content of from about 0% to about 16%, by weight of the product). Unless otherwise described herein, wet composition, moist composition and/ or dry composition are not limited by their composition or method of preparation.


The composition herein can be complete and nutritionally balanced. A complete and nutritionally balanced animal food composition may be compounded to be fed as the sole ration and is capable of maintaining the life and/or promote reproduction without any additional substance being consumed, except for water.


The composition and components of the present invention are selected for consumption by an animal and are not intended for consumption by humans. Non-limiting examples of compositions include supplements for an animal, pet food, dog food, cat food, treats, biscuits, raw hide, treats, chews, fillers gravy, sauce, beverage, supplemental water, and combinations thereof.


Additionally, administration in accordance with the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.


Glucose Anti-Abolite


The method of the present invention comprise administering to a mammal a composition that can comprise a glucose anti-metabolite. The glucose anti-metabolites affects the level of CRP present in the blood of a mammal by decreasing inflammation and therefore resulting in decreased CRP levels subsequent to a mammal ingesting a composition comprising glucose anti-metabolites.


The level of C-reactive protein in the blood subsequent to administration of a composition comprising a glucose anti-metabolite is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.


Nonlimiting examples of glucose anti-metabolites which are useful herein include 2-deoxy-D-glucose, 5-thio-D-glucose, 3-O-methylglucose, anhydrosugars including 1,5-anhydro-D-glucitol, 2,5-anhydro-D-glucitol, and 2,5-anhydro-D-mannitol, and mannoheptulose. Mannoheptulose is preferred for use herein.


The dose of glucose anti-metabolites given to a mammal, on a daily basis, is from about 0.1 mg/kg to about 1000 mg/kg, from about 2 mg/kg to about 100 mg/kg, from about 2 mg/kg to about 10 mg/kg, wherein (as will be commonly understood in the art) the “mg” refers to level of the component and the “kg” refers to kilograms of the mammal or from about 0.0001 gram to about 1 gram of glucose anti-metabolites per kilogram of the mammal. When glucose anti-metabolites is present in a composition, the glucose anti-metabolites is less than about 5%, or less than about 2%, or from about 0.0001% to about 0.5% of the glucose anti-metabolites, all by weight of the composition. The level of component may be determined by one of ordinary skill in the art based on a variety of factors, for example, the form of the pet food composition (e.g., whether a dry composition, moist composition, wet composition, or supplement, or any other form or mixture thereof). The ordinarily skilled artisan will be able to utilize the preferred optimal doses, and use these to determine the optimal level of component within a given pet food composition.


When the glucose anti-metabolite is mannoheptulose the dose of mannoheptulose given to a mammal, on a daily basis, is from about 0.1 mg/kg to about 1000 mg/kg, from about 1 mg/kg to about 100 mg/kg, from about 2 mg/kg to about 5 mg/kg, wherein (as will be commonly understood in the art) the “mg” refers to level of the mannoheptulose and the “kg” refers to kilograms of the mammal or from about 0.0001 gram to about 1 gram of mannoheptulose per kilogram of the mammal. When mannoheptulose is present in a composition, the mannoheptulose is less than about 5%, or less than about 2%, or from about 0.0001% to about 0.5% of the mannoheptulose, all by weight of the composition.


The level of C-reactive protein in the blood subsequent to administration of a composition comprising a mannoheptulose is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.


Avocado


The method of the present invention comprises administering to a mammal a composition that can comprise avocado. The avocado affects the level of CRP present in the blood of a mammal by decreasing inflammation and stress and therefore resulting in decreased CRP levels subsequent to a mammal ingesting a composition comprising avocado.


The level of C-reactive protein in the blood subsequent to administration of a composition comprising an avocado is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.


An avocado (also commonly referred to as alligator pear, aguacate, or palta) contains unusually enriched sources of mannoheptulose, as well as related sugars and other carbohydrates. Avocado is a sub-tropical evergreen tree fruit, growing most successfully in areas of California, Florida, Hawaii, Guatemala, Mexico, the West Indies, South Africa, and Asia.


Nonlimiting examples of species of avocado that can be used in the present invention include, for example, Persea Americana and Persea nubigena, including all cultivars within these illustrative species. Cultivars may include ‘Anaheim,’ ‘Bacon,’ ‘Creamhart,’ ‘Duke,’ ‘Fuerte,’ ‘Ganter,’ ‘Gwen,’ ‘Hass,’ ‘Jim,’ ‘Lula,’ ‘Lyon,’ ‘Mexicola,’ ‘Mexicola Grande,’ ‘Murrieta Green,’ ‘Nabal,’ ‘Pinkerton,’ ‘Queen,’ ‘Puebla,’ ‘Reed,’ ‘Rincon,’ ‘Ryan,’ ‘Spinks,’ ‘Topa Topa,’ ‘Whitsell,’ ‘Wurtz,’ and ‘Zutano.’ The fruit of the avocado is particularly preferred for use herein, which may contain the pit or wherein the pit is removed or at least partially removed. Fruit from Persea Americana is particularly preferred for use herein, as well as fruit from cultivars which produce larger fruits (e.g., about 12 ounces or more when the fruit is mature), such as Anaheim, Creamhart, Fuerte, Hass, Lula, Lyon, Murrieta Green, Nabal, Queen, Puebla, Reed, Ryan, and Spinks.


The dose of avocado given to a mammal, on a daily basis, is from about 100 mg/kg to about 200 g/kg, from about 200 mg/kg to about 20 g/kg, from about 400 mg/kg to about 10 g/kg, wherein (as will be commonly understood in the art) the “mg” or “g” refers to level of avocado and the “kg” refers to kilograms of the mammal or from about 0.001 gram to about 200 gram of avocado per kilogram of the mammal. When avocado is present in a composition, the avocado is less than about 50%, or less than about 25%, or from about 0.0001% to about 5% of the avocado, all by weight of the composition. The level of avocado may be determined by one of ordinary skill in the art based on a variety of factors, for example, the form of the composition (e.g., whether a dry composition, moist composition, wet composition, or supplement, or any other form or mixture thereof). The ordinarily skilled artisan will be able to utilize the preferred optimal doses, and use these to determine the optimal level of component within a given composition.


Advantageously, mannoheptulose or any other component may be present in the recited compositions as a component of plant matter such as avocado, or other enriched source of mannoheptulose such as alfalfa, fig, or primrose. The plant matter may include the fruit, seed (or pit), branches, leaves, or any other portion of the relevant plant or combination thereof. Additionally, plant matter from alfalfa, fig, or primrose is also reported to provide relatively high levels of mannoheptulose. Alfalfa is also referred to as Medicago sativa. Fig, or Ficus carica (including Cluster fig or Sycamore fig, for example) may also be used, as well as primrose or Primula officinalis.


The mannoheptulose or any other component can be extracted from the plant matter and or avocado to form a plant extract or component extract or avocado extract and then utilized in the composition of the present invention.


When an extract of plant matter is utilized in a composition herein, the component will be present from about 1% to about 99% of the component extract, from about 5% to about 75% of the component extract, from about 10% to about 50% of the component extract, all by weight of the extract.


When an avocado extract is utilized in a composition herein, the component will be present from about 1% to about 99% of the component extract, from about 5% to about 75% of the component extract, from about 10% to about 50% of the component extract, all by weight of the extract.


When an extract of plant matter is mannoheptulose and then utilized in a composition herein, the mannoheptulose will be present from about 1% to about 99% of mannoheptulose, from about 5% to about 75% of the mannoheptulose, from about 10% to about 50% of the mannoheptulose, all by weight of the extract.


When an extract of avocado is mannoheptulose and then utilized in a composition herein, the mannoheptulose will be present from about 1% to about 99% of mannoheptulose, from about 5% to about 75% of the mannoheptulose, from about 10% to about 50% of the mannoheptulose, all by weight of the extract.


The dose of mannoheptulose used when obtained from a plant or avocado extract that is given to a mammal, on a daily basis, is from about 0.1 mg/kg to about 1000 mg/kg, from about 2 mg/kg to about 100 mg/kg, from about 2 mg/kg to about 5 mg/kg, wherein (as will be commonly understood in the art) the “mg” or “g” refers to level of the mannoheptulose and the “kg” refers to kilograms of the mammal or from about 0.001 gram to about 1 gram of mannoheptulose per kilogram of the mammal. When mannoheptulose obtained from a plant extract or avocado extract is present in a composition, the mannoheptulose is less than about 5%, or less than about 2%, or from about 0.0001% to about 0.5% of the mannoheptulose, all by weight of the composition. The level of mannoheptulose may be determined by one of ordinary skill in the art based on a variety of factors, for example, the form of the composition (e.g., whether a dry composition, moist composition, wet composition, or supplement, or any other form or mixture thereof). The ordinarily skilled artisan will be able to utilize the preferred optimal doses, and use these to determine the optimal level of component within a given composition.


The level of C-reactive protein in the blood subsequent to administration of a composition comprising an extract of mannoheptulose obtained from plant matter or avocado extract is from about 0 mg/L to about 100 mg/L, from about 0.1 mg/L to about 60 mg/L, from about 0.2 mg/L to about 40 mg/L, from about 0.3 mg/L to about 20 mg/L.


Compositions


It is anticipated that the glucose anti-metabolite or avocado or mannoheptulose or avocado extract described in the present invention can be added to any composition adapted for administration to a mammal.


Typical formulae for compositions are well known in the art. In addition to proteinaceous and farinaceous materials, the compositions of the invention generally may include vitamins, minerals, and other additives such as flavorings, preservatives, emulsifiers and humectants. The nutritional balance, including the relative proportions of vitamins, minerals, protein, fat and carbohydrate, is determined according to dietary standards known in the veterinary and nutritional art.


Nonlimiting examples of dry compositions may optionally contain on a dry matter basis, from about 1% to about 50% crude protein, from about 0.5% to about 25% crude fat, from about 1% to about 10% supplemental fiber, all by weight of the composition. The dry composition may have a total moisture content from about 1% to about 30% moisture. Alternatively, a dry composition may contain on a dry matter basis, from about 5% to about 35% crude protein, from about 5% to about 25% crude fat, from about 2% to about 8% supplemental fiber, all by weight of the composition. The dry composition may have a total moisture content from about 2% to about 20% moisture. Alternatively, the dry composition contains on a dry matter basis, a minimum protein level of about from about 9.5% to about 35%, a minimum fat level of from about 8% to about 20%, a minimum supplemental fiber level of from about 3% to about 7%, all by weight of the composition. The dry animal composition may also have a minimum metabolizable energy level of about 3.5 Kcal/g. The dry composition may have a total moisture content from about 3% to about 10%,


Nonlimiting examples of a semi-moist composition may optionally contain on a dry matter basis, from about 0.5% to about 50% crude protein, from about 0.5% to about 25% crude fat, from about 0.5% to about 15% supplemental fiber, all by weight of the composition. The semi-moist composition may have a total moisture content from about 30% to about 50% moisture. Alternatively, the semi-moist compositions may contain on a dry matter basis, from about 5% to about 35% crude protein, from about 5% to about 25% crude fat, from about 1% to about 5% supplemental fiber, and all by weight of the composition. The semi-moist composition may have a total moisture content from about 35% to about 45% moisture. Alternatively, the semi-moist composition may have on a dry matter basis, a minimum protein level of about from about 9.5% to about 22%, a minimum fat level of from about 8% to about 13%, a minimum supplemental fiber level of from about 2% to about 3%, all by weight of the composition. The semi-moist composition may have a total moisture content from about 38% to about 42%. The semi-moist composition may also have a minimum metabolizable energy level of about 3.5 Kcal/g and from about 0.1% to about 20% ash, and from about 0.001% to about 5.0% taurine.


Nonlimiting examples of a moist composition may optionally contain on a dry matter basis, from about 0.5% to about 50% crude protein, from about 0.5% to about 25% crude fat, from about 0.01% to about 15% supplemental fiber, all by weight of the composition. The moist composition may have a total moisture content from about 50% to about 90% moisture. Alternatively, the moist compositions may contain on a dry matter basis, from about 5% to about 35% crude protein, from about 5% to about 25% crude fat, from about 0.05% to about 5% supplemental fiber, all by weight of the composition. The moist composition may have a total moisture content from about 60% to about 85% moisture. Alternatively, a moist animal composition may contain on a dry matter basis, a minimum protein level of about from about 9.5% to about 22%, a minimum fat level of from about 8% to about 13%, a minimum supplemental fiber level of from about 0.1% to about 3%, all by weight of the composition. The moist composition may have a total moisture content from about 65% to about 80%. The moist composition may also have a minimum metabolizable energy level of about 1.0 Kcal/g and from about 0.1% to about 20% ash, and from about 0.001% to about 5.0% taurine.


In one embodiment of the present invention, the composition is a composition, whether dry, moist, semi-moist or otherwise, that comprises on a dry matter basis, from about 5% to about 50%, alternatively 20% to about 50% of animal-derived ingredients, by weight of the composition. Non-limiting examples of animal-derived ingredients include chicken, beef, pork, lamb, turkey (or other animal) protein or fat, egg, fishmeal, and the like.


Where the composition is in the form of a gravy, the composition may comprise at least 10% of a broth, or stock, non-limiting examples of which include vegetable beef, chicken or ham stock. Typical gravy compositions may comprise on a dry matter basis, from about 0.5% to about 5% crude protein, and from about 2% to about 5% crude fat.


Where the composition is in the form of a supplement composition such as biscuits, chews, and other treats, the supplement may comprise, on a dry matter basis, from about 20% to about 60% protein, from about 22% to about 40% protein, by weight of the supplement composition. As another example, the supplement compositions may comprise, on a dry matter basis, from about 5% to about 35% fat, or from about 10% to about 30% fat, by weight of the supplement composition. Compositions and supplement compositions intended for use by animals such as cats or dogs are commonly known in the art.


Optional Ingredients


The composition of the present invention can further comprise a wide range of other optional ingredients.


Nonlimiting examples of additional components include animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, textured wheat protein, textured soy protein, textured lupin protein, textured vegetable protein, breading, comminuted meat, flour, comminuted pasta, water, and combinations thereof.


Nonlimiting examples of optional ingredients can include at least one vegetable. Nonlimiting examples of vegetables include carrots, peas, potatoes, cabbage, celery, beans, corn, tomatoes, broccoli, cauliflower, leeks and combinations thereof.


Also useful herein, as an optional ingredient, is a filler. The filler can be a solid, a liquid or packed air. The filler can be reversible (for example thermo-reversible including gelatin) and/or irreversible (for example thermo-irreversible including egg white). Nonlimiting examples of the filler include gravy, gel, jelly, aspic, sauce, water, air (for example including nitrogen, carbon dioxide, and atmospheric air), broth, and combinations thereof.


Nonlimiting examples of colorants include, but are not limited to, synthetic or natural colorants, and any combination thereof. When present the colorants are from about 0.0001% to about 5%, more from about 0.001% to about 1%, even more from about 0.005% to about 0.1%, on a dry matter basis, of said colorant.


Additionally, probiotic microorganisms, such as Lactobacillus or Bifidobacterium species, for example, may be added to the composition or the animal food compositions themselves.


Also useful herein, as an optional ingredient, is at least one fruit. Nonlimiting examples include tomatoes, apples, pears, peaches, cherries, apricots, plums, grapes, oranges, grapefruit, lemons, limes, cranberries, raspberries, blueberries, watermelon, cantelope, mushmellon, honeydew melon, strawberries, banana, and combinations thereof.


The composition may contain other active agents such as long chain fatty acids and zinc. Suitable long chain fatty acids include alpha-linoleic acid, gamma linolenic acid, linoleic acid, eicosapentanoic acid, and docosahexanoic acid. Fish oils are a suitable source of eicosapentanoic acids (EPA) and docosahexanoic acid (DHA). The DHA level is at least about 0.05%, alternatively at least about 0.1%, alternatively at least about 0.15% of the animal food composition, all on a dry matter basis. The EPA level is at least about 0.05%, alternatively at least about 0.1%, alternatively at least about 0.15% of the animal food composition, all on a dry matter basis.


The compositions of the present invention may further comprise a source of carbohydrate. Grains or cereals such as rice, corn, milo, sorghum, barley, wheat, and the like are illustrative sources.


The compositions may also contain other materials such as dried whey and other dairy by products.


Optional Processes for Preparing the Compositions of the Present Invention


The compositions may be prepared by any of a variety of processes including, but not limited to, optional processes described herein. Disclosed herein are optional processes for preparing the present inventive compositions. The ordinarily skilled artisan will understand, however, that the compositions are not limited by the following described processes.


A process for preparing the present compositions may comprise:

    • (a) providing plant matter;
    • (b) combining the plant matter with an aqueous solution and optionally with an enzyme, further optionally with heating, to provide a digested plant mixture;
    • (c) optionally separating any fractions present in the digested plant mixture, if any, to provide a carbohydrate extract;
    • (d) concentrating the digested plant mixture to enhance the concentration of carbohydrate therein; and
    • (e) combining the digested plant mixture with one or more composition components.


The plant matter may be any portion or whole of the plant, such as the leaves, fruit, seed or pit. In one optional process herein, the avocado is provided, and the process may commence with whole avocado fruit, including the pit or devoid (or partially devoid) of the pit. If the plant matter which is provided contains a pit, or partial pit, the pit or portion thereof may be optionally removed prior to further processing. Alfalfa, fig, or primrose may be similarly processed.


Additionally, in the production of a digested plant mixture can comprise combination of the plant matter with an aqueous solution, such as water, to assist with maceration of the plant into manageable constituents. Optionally but preferably, an enzyme having cellulose or pectin activity, or any combination thereof (such as a cellulase, hemicellulase, or pectinase) is included to assist with such maceration, including to assist with dissolution and release of carbohydrates via cell wall disruption. The utility of such an enzymatic treatment may be enhanced through heating during such maceration, such as from above ambient temperature to about 120° C., or to about 100° C., or from about 60° C. to about 120° C., or from about 60° C. to about 100° C. Agitation is further preferably utilized, typically for up to about 24 hours, but dependent upon the batch under processing. In one embodiment, the pH is controlled such to preserve enzyme activity, often in the range of pH from about 4 to about 6, preferably in the range of pH from about 5 to about 6. As such, depending upon such factors as ripeness of plant matter, quality of process aqueous solution (such as water added for process, for example), and the like, amounts of acid or base may be desirable as will be appreciated by one of ordinary skill in the art. Optionally, to assist with deactivation of the enzymes present, heating may be increased at the time of, or after, initial heating and agitation to form the digested plant mixture. Water is optionally heated to processing temperatures prior to the addition of the plant matter. Heat may be applied by a jacketed tank where low pressure steam is utilized. The digested plant mixture may result in fractions which may be separated in accordance with common techniques. For example, fractions present in the digested plant mixture may be separated by filtration to provide the carbohydrate extract as the resulting filtrate, with the filter cake being discarded. Other methods may include, but not be limited to, gravimetric, centrifugal, other filtrations, or combinations thereof.


The carbohydrate extract may then be concentrated, optionally utilizing at least one concentration method selected from the group consisting of heating, vacuum drying, evaporation, refractance window drying, freeze drying, spray drying, any other useful technique, or any combination of the foregoing. In one embodiment, at least one technique such as refractance window drying is used.


Once concentrated, the carbohydrate extract may be utilized in a composition of the present invention. In one embodiment herein, the present processes result in preferred yields of mannoheptulose or other components, based on the starting mass of the plant matter (e.g., avocado). In one embodiment, the yield of mannoheptulose present in the carbohydrate extract subsequent to concentration is less than about 20%, or from about 0.1% to about 10%, or from about 1% to about 7%, based on the starting mass of the plant matter. In another embodiment, the yield of the carbohydrate extract subsequent to concentration is less than about 30%, or from about 5% to about 25%, or from about 8% to about 20%, based on the starting mass of the plant matter. Of course, even higher yields may be desirable, and lower yields may also be acceptable.


C-Reactive Protein (CRP) Procedure


CRP analysis using Diasorin reagents (cat. No. 86083) has been adapted for use on the Hitachi 911 automated chemistry analyzer for samples. All samples are analyzed on the decreased sample size function of the Hitachi 911. Components of the Diasorin kit include polymer diluent, antibody reagent, and saline. CRP calibration standards and a human CRP control (cat. No. 86108) are used to generate a calibration curve and ensure the method is calibrated properly. The Diasorin CRP analysis is an immunopreciptin analysis. The sample and antiserum are mixed together forming insoluble complexes that produce turbidity and scatter light. The absorbance is then measured. Sample concentrations are interpolated from the calibration curve. Polymer diluent is used as is for T1 which dispenses 10 seconds after sample dispense. Antibody reagent diluted 1:7 with saline is used for T3 which dispenses 5 minutes after T1 is dispensed. The calibration type used is a full type using a blank (saline) and at least 3 programmed standards, 5 standards are used to ensure a broad range. The Diasorin kit comes with 5 standards, but we do not use the 100 standard (#5) and we dilute standard #2 1:10 with saline to increase our sensitivity range. Calibration type is Logit-Log 4P. The analysis uses a 2 point end (sample-blanked endpoint assay) with a primary wavelength of 340 nm and secondary wavelength of 700 nm. The CRP control and saline sample are analyzed with each run. After sample analysis has been completed a reaction monitor is viewed and printed for each sample. The reaction monitor allows a view in graph form of the photometric absorbance vs time. For CRPs cells are measured at 1-5, 6-10, 11-5, 16-20, 26-30, and 31-35. Cells 16-20 are compared with cells 31-35 and if cells 16-20 are higher than 31-35 a dilution must be performed (1:5 with saline) and the sample reanalyzed. Also all samples that read 0.0 upon initial analysis are diluted and reanalyzed to prevent false negative results, regardless of the cell comparisons. Results are reported in units of mg/L.


NOTE: Calibration standard values change periodically and should be put into the chemistry parameters of the Hitachi 911 when changed under the chemistry parameters menu.


Total Moisture Content Method


The method involves the analysis of the total moisture content in the composition. The analysis is based on the procedure outlined in AOAC method 930.15 and AACC method 44-19.


A composition sample is prepared by taking one unit volume, for example, 375 gram of the composition, and homogenizing in a food processor to a uniform consistency like a paste. A composition larger than 375 gram would be subdivided to create equal and representative fractions of the whole such that a 375 gram sample is obtained.


The paste of the composition is individually sampled in triplicate at a volume less than or equal to 100 ml and placed individually sealed in a 100 ml Nasco Whirl-Pak® (Fort Atkinson, Wis. 53538-0901). During the process of sealing the Whirl-Pak®, excess air is evacuated manually from the container just prior to final closure thereby minimizing the container headspace. The Whirl-Pak® is closed per manufacturer's instructions—tightly folding the bag over three (3) times and bending the tabs over 180 degrees.


All samples are refrigerated at 6° C. for less than 48 h prior to moisture analysis.


For total moisture analysis, the tare weight of each moisture tin and lid are recorded to 0.0001 g. Moisture tins and lids are handled using dry and clean forceps. Moisture tins and lids are held dry over desiccant in a sealed desiccator. A Whirl-Pak® containing a sample is unfolded and a 2.0000+/−0.2000 gram sample is weighed into the uncovered moisture tin. The weight of the sample in the moisture tin is recorded. The lid is placed atop the moisture tin in an open position to allow moisture loss but contain all other material during air oven drying. The lid and moisture tin loaded with sample are placed in an air oven operating at 135° C. for 6 h. Time is tracked using a count-down timer.


After drying, the tin is removed from the oven and the dried lid is placed atop the tin using forceps. The covered moisture tin with dried sample is placed immediately in a desiccator to cool. The sealed desiccator is filled below the stage with active desiccant. Once cool to room temperature, the covered moisture tin with dried sample is weighed to 0.0001 g and weight recorded. The total moisture content of each sample is calculated using the following formula:

Total Moisture Content(%)=100−(weight of tin, lid and sample after drying−empty tin and lid weight)×100 /initial sample weight.


EXAMPLES

The following examples further describe and demonstrate embodiments within the scope of the invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention. All of the following examples are compositions that are utilized by a mammal.


Examples 1-72











Dry compositions

















Percentage % on dry matter basis (w/w)













Ingredient
Example 1
Example 2
Example 3
Example 4
Example 5
Example 6





Protein products and meals
26.4000
42.0000
45.3000
55.8000
56.0000
37.0000


Cereal grains
64.0500
43.0500
37.6500
27.4500
26.7500
45.9500


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
8.0000
7.0000


Avocado Extract
0.0500
0.0500
0.0500
0.0500
0.0500
0.0500












Percentage % on dry matter basis (w/w)













Ingredient
Example 7
Example 8
Example 9
Example 10
Example 11
Example 12





Protein products and meals
26.4000
42.0000
45.3000
55.8000
56.0000
37.0000


Cereal grains
64.0975
43.0975
37.6975
27.4975
26.7975
45.9975


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
8.0000
7.0000


Avocado Extract
0.0025
0.0025
0.0025
0.0025
0.0025
0.0025












Percentage % on dry matter basis (w/w)













Ingredient
Example 13
Example 14
Example 15
Example 16
Example 17
Example 18





Protein products and meals
21.4000
37.0000
40.2000
50.7000
51.0000
32.0000


Cereal grains
59.1000
38.1000
32.8000
22.6000
21.8000
41.0000


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
8.0000
7.0000


Avocado Extract
10.0000
10.0000
10.0000
10.0000
10.0000
10.0000












Percentage % on dry matter basis (w/w)













Ingredient
Example 19
Example 20
Example 21
Example 22
Example 23
Example 24





Protein products and meals
25.9000
48.0000
45.0000
54.9000
56.0000
50.0000


Cereal grains
63.6000
36.1000
37.0000
27.4000
26.8000
32.0000


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Avocado
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000












Percentage % on dry matter basis (w/w)













Ingredient
Example 25
Example 26
Example 27
Example 28
Example 29
Example 30





Protein products and meals
25.9000
48.0000
45.0000
54.9000
56.0000
50.0000


Cereal grains
39.6000
12.1000
13.0000
3.4000
2.8000
8.0000


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Avocado
25.0000
25.0000
25.0000
25.0000
25.0000
25.0000












Percentage % on dry matter basis (w/w)













Ingredient
Example 31
Example 32
Example 33
Example 34
Example 35
Example 36





Protein products and meals
26.4000
48.5000
45.5000
55.4000
56.5000
50.5000


Cereal grains
64.0500
36.5500
37.4500
27.8500
27.2500
32.4500


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Avocado
0.0500
0.0500
0.0500
0.0500
0.0500
0.0500












Percentage % on dry matter basis (w/w)













Ingredient
Example 37
Example 38
Example 39
Example 40
Example 41
Example 42





Protein products and meals
26.4000
48.5000
45.0000
55.4000
56.5000
50.0000


Cereal grains
64.0800
36.5800
37.9800
27.8800
27.2800
32.9800


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Mannoheptulose
0.0200
0.0200
0.0200
0.0200
0.0200
0.0200












Percentage % on dry matter basis (w/w)













Ingredient
Example 43
Example 44
Example 45
Example 46
Example 47
Example 48





Protein products and meals
26.4000
48.4000
45.0000
55.4000
56.5000
50.0000


Cereal grains
64.0990
36.6990
37.9990
27.8990
27.2990
32.9990


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Mannoheptulose
0.0010
0.0010
0.0010
0.0010
0.0010
0.0010












Percentage % on dry matter basis (w/w)













Ingredient
Example 49
Example 50
Example 51
Example 52
Example 53
Example 54





Protein products and meals
21.4000
43.4000
40.0000
50.4000
51.5000
45.0000


Cereal grains
59.1000
31.7000
33.0000
22.9000
22.3000
28.0000


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Mannoheptulose
10.0000
10.0000
10.0000
10.0000
10.0000
10.0000












Percentage % on dry matter basis (w/w)













Ingredient
Example 55
Example 56
Example 57
Example 58
Example 59
Example 60





Protein products and meals
26.4000
48.4000
45.0000
55.4000
56.5000
50.0000


Cereal grains
64.0800
36.6800
37.9800
27.8800
27.2800
32.9800


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Glucose Anti-Metabolite
0.0200
0.0200
0.0200
0.0200
0.0200
0.0200












Percentage % on dry matter basis (w/w)













Ingredient
Example 61
Example 62
Example 63
Example 64
Example 65
Example 66





Protein products and meals
26.4000
48.4000
45.0000
55.4000
56.5000
50.0000


Cereal grains
64.0990
36.6990
37.9990
27.8990
27.2990
32.9990


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Glucose Anti-Metabolite
0.0010
0.0010
0.0010
0.0010
0.0010
0.0010












Percentage % on dry matter basis (w/w)













Ingredient
Example 67
Example 68
Example 69
Example 70
Example 71
Example 72





Protein products and meals
21.4000
43.5000
40.0000
50.4000
51.5000
45.0000


Cereal grains
59.1000
31.6000
33.0000
22.9000
22.3000
28.0000


Fat
2.6000
5.8000
7.0000
6.0000
6.0000
7.0000


Egg product
3.5000
2.0000
3.0000
2.0000
2.0000
2.0000


Vitamins
0.2000
0.4000
0.6000
0.8000
0.4000
0.4000


Minerals
0.2000
0.8000
0.4000
0.8000
0.8000
0.6000


Fiber
3.0000
5.9000
6.0000
7.1000
7.0000
7.0000


Glucose Anti-Metabolite
10.0000
10.0000
10.0000
10.0000
10.0000
10.0000










The dry compositions of Examples 1-72 can be made by first, milling and mixing the cereal grains with protein meal, egg products, vitamins and minerals and fiber sources and avocado or avocado extract or mannoheptulose or glucose anti-metabolite. Then, add the mixed, dried ingredients to the meat products and fat sources. Extrude the ingredients into kibbles. Dry the kibbles. Package the finished product.


Examples 73-144











Wet compositions

















Percentage % on matter basis (w/w)













Ingredient
Example 73
Example 74
Example 75
Example 76
Example 77
Example 78





Protein products and meal
82.7000
44.9000
54.0000
65.3000
63.4000
48.4000


Cereal grains
11.4000
43.7000
35.9000
29.9000
30.1000
45.7000


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Avocado Extract
0.2000
0.2000
0.2000
0.2000
0.2000
0.2000












Percentage % on dry matter basis (w/w)













Ingredient
Example 79
Example 80
Example 81
Example 82
Example 83
Example 84





Protein products and meal
82.7000
44.9000
54.0000
65.4000
63.5000
48.4000


Cereal grains
11.5900
43.8900
36.0900
29.9900
30.1900
45.8900


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Avocado Extract
0.0100
0.0100
0.0100
0.0100
0.0100
0.0100












Percentage % on dry matter basis (w/w)













Ingredient
Example 85
Example 86
Example 87
Example 88
Example 89
Example 90





Protein products and meal
72.7000
35.0000
44.1000
55.4000
53.5000
38.5000


Cereal grains
1.6000
33.8000
25.0000
20.0000
20.2000
35.8000


Fat
0.0000
2.0000
2.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Avocado Extract
20.0000
20.0000
20.0000
20.0000
20.0000
20.0000












Percentage % on dry matter basis (w/w)













Ingredient
Example 91
Example 92
Example 93
Example 94
Example 95
Example 96





Protein products and meal
80.7000
43.0000
52.1000
63.4000
61.5000
46.5000


Cereal grains
9.6000
41.8000
34.0000
28.0000
28.2000
43.8000


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Avocado
4.0000
4.0000
4.0000
4.0000
4.0000
4.0000












Percentage % on dry matter basis (w/w)

















Example

Example


Ingredient
Example 97
Example 98
Example 99
100
Example 101
102





Protein products and meal
82.6000
44.9000
54.0000
65.3000
63.4000
48.4000


Cereal grains
11.5000
43.7000
35.9000
29.9000
30.1000
45.7000


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Avocado
0.2000
0.2000
0.2000
0.2000
0.2000
0.2000












Percentage % on dry matter basis (w/w)














Example

Example
Example

Example


Ingredient
103
Example 104
105
106
Example 107
108





Protein products and meal
72.7000
35.0000
44.1000
55.4000
53.5000
38.5000


Cereal grains
1.6000
33.8000
26.0000
20.0000
20.2000
35.8000


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Avocado
20.0000
20.0000
20.0000
20.0000
20.0000
20.0000












Percentage % on dry matter basis (w/w)
















Example
Example

Example


Ingredient
Example 109
Example 110
111
112
Example 113
114





Protein products and meal
82.7000
44.9000
54.0000
65.3000
63.4000
48.3000


Cereal grains
11.5200
43.8200
35.0200
30.0200
30.2200
45.9200


Fat
0.0000
2.0000
2.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Mannoheptulose
0.0800
0.0800
0.0800
0.0800
0.0800
0.0800












Percentage % on dry matter basis (w/w)
















Example
Example

Example


Ingredient
Example 115
Example 116
117
118
Example 119
120





Protein products and meal
82.7000
44.9000
54.0000
65.4000
63.5000
48.4000


Cereal grains
11.5960
43.8960
36.0960
29.9960
30.1960
45.8960


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Mannoheptulose
0.0040
0.0040
0.0040
0.0040
0.0040
0.0040












Percentage % on dry matter basis (w/w)
















Example
Example

Example


Ingredient
Example 121
Example 122
123
124
Example 125
126





Protein products and meal
77.7000
40.0000
49.1000
60.4000
58.5000
43.5000


Cereal grains
6.6000
38.8000
31.0000
25.0000
25.2000
40.8000


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Mannoheptulose
10.0000
10.0000
10.0000
10.0000
10.0000
10.0000












Percentage % on dry matter basis (w/w)
















Example
Example

Example


Ingredient
Example 127
Example 128
129
130
Example 131
132





Protein products and meal
82.7000
44.9000
54.0000
65.3000
63.4000
48.3000


Cereal grains
11.5200
43.8200
35.0200
30.0200
30.2200
45.9200


Fat
0.0000
2.0000
2.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Glucose Anti-Metabolite
0.0800
0.0800
0.0800
0.0800
0.0800
0.0800












Percentage % on dry matter basis (w/w)
















Example
Exampl3

Example


Ingredient
Example 133
Example 134
135
136
Example 137
138





Protein products and meal
82.7000
44.9000
54.0000
65.4000
63.5000
48.4000


Cereal grains
11.5960
43.8960
36.0960
29.9960
30.1960
45.8960


Fat
0.0000
2.0000
1.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Glucose Anti-Metabolite
0.0040
0.0040
0.0040
0.0040
0.0040
0.0040












Percentage % on dry matter basis (w/w)
















Example
Example

Example


Ingredient
Example 139
Example 140
141
142
Example 143
144





Protein products and meal
77.7000
40.0000
49.1000
60.4000
58.5000
43.5000


Cereal grains
6.6000
38.8000
30.0000
25.0000
25.2000
40.8000


Fat
0.0000
2.0000
2.0000
1.0000
1.0000
2.0000


Egg product
2.5000
2.0000
3.0000
2.0000
2.0000
3.4000


Vitamins
0.1000
0.4000
0.6000
0.8000
0.4000
0.1000


Minerals
0.1000
0.8000
0.4000
0.8000
0.4000
0.2000


Fiber
3.0000
6.0000
4.9000
0.0000
2.5000
0.0000


Glucose Anti-Metabolite
10.0000
10.0000
10.0000
10.0000
10.0000
10.0000









The wet compositions of Examples 73-144 can be made by first drying and milling cereal grains. Mix dried cereal grains, Protein meals, egg product, vitamins, minerals and fiber sources and avocado or avocado extract or mannoheptulose or glucose anti-metabolite. Blend dry ingredients with meat products and fat sources. The mixture is packaged into cans and cooked via retort process to provided finished product. For preformed pieces (chunks in gravy) mixture is extruded, passed through a steam tunnel for preconditioning, cut to desired shape, packaged with added water and retorted to provide safe finished product.


It should be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification includes every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification includes every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.


All parts, ratios, and percentages herein, in the Specification, Examples, and Claims, are by weight and all numerical limits are used with the normal degree of accuracy afforded by the art, unless otherwise specified.


All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.


While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims
  • 1. A method for decreasing inflammation and stress in a mammal comprising: administration to a mammal a composition comprising avocado fruit; and wherein said composition comprises amounts of the avocado fruit sufficient to lower a level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado; wherein administration is daily and the dose of avocado fruit is about 100 mg/kg to about 200 g/kg; and wherein the composition comprises less than 5% of said avocado fruit, by weight of the composition.
  • 2. The method of claim 1, wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado is from about 0 mg/L to about 100 mg/L.
  • 3. The method of claim 1, wherein the administration is oral.
  • 4. The method of claim 1, wherein said composition is selected from the group consisting of pet food, dog food, cat food, treats, chew, biscuits, gravy, sauce, beverage, supplemental water, and combinations thereof.
  • 5. The method of claim 4, wherein the composition is a nutritionally balanced pet food composition.
  • 6. The method of claim 1, further comprising animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, lipids, and combinations thereof.
  • 7. The method of claim 1, wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado is from about 0 mg/L to about 100 mg/L.
  • 8. A method for decreasing inflammation and stress in a mammal comprising: administration to a mammal a composition comprising mannoheptulose; and wherein said composition comprises amounts of the mannoheptulose sufficient to lower the level of a C-reactive protein in the blood of the mammal subsequent to administration of the mannoheptulose; wherein administration is daily and the dose of mannoheptulose is about 2 mg/kg to about 5 mg/kg; and wherein the composition comprises less than 5% of said mannoheptulose, by weight of the composition.
  • 9. The method of claim 8, wherein the level of said C-reactive protein in the blood subsequent to administration of the mannoheptulose is from about 0 mg/L to about 100 mg/L.
  • 10. The method of claim 8, wherein the level of said C-reactive protein in the blood subsequent to administration of the mannoheptulose is from about 0.1 mg/L to about 60 mg/L.
  • 11. The method of claim 8, wherein the level of said C-reactive protein in the blood subsequent to administration of the mannoheptulose is from about 0.2 mg/L to about 40 mg/L.
  • 12. The method of claim 8, wherein said mannoheptulose is selected from the group consisting of avocado extract, avocado, and combinations thereof.
  • 13. The method of claim 8, wherein the administration is oral.
  • 14. The method of claim 8, wherein said composition is selected from the group consisting of pet food, dog food, cat food, treats, chew, biscuits, gravy, sauce, beverage, supplemental water, and combinations thereof.
  • 15. The method of claim 8, wherein the composition is a nutritionally balanced pet food composition.
  • 16. The method of claim 8, further comprising animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, lipids, and combinations thereof.
  • 17. A method for decreasing inflammation and stress in a mammal comprising: administration to a mammal a composition comprising avocado extract; and wherein said composition comprises amounts of the avocado extract sufficient to lower the level of a C-reactive protein in the blood of the mammal subsequent to administration of the avocado extract; wherein administration is daily and the avocado extract comprises a dose of glucose anti-metabolite at about 2 mg/kg to about 5 mg/kg; and wherein the composition comprises less than 5% of said avocado extract, by weight of the composition.
  • 18. The method of claim 17, wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado extract is from about 0 mg/L to about 100 mg/L.
  • 19. The method of claim 17, wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado extract is from about 0.1 mg/L to about 60 mg/L.
  • 20. The method of claim 17, wherein the level of said C-reactive protein in the blood subsequent to administration of the avocado extract is from about 0.2 mg/L to about 40 mg/L.
  • 21. The method of claim 17, wherein the administration is oral.
  • 22. The method of claim 17, wherein said composition is selected from the group consisting of pet food, dog food, cat food, treats, chew, biscuits, gravy, sauce, beverage, supplemental water, and combinations thereof.
  • 23. The method of claim 17, wherein the composition is a nutritionally balanced pet food composition.
  • 24. The method of claim 17 further comprising animal protein, plant protein, farinaceous matter, vegetables, fruit, egg-based materials, undenatured proteins, food grade polymeric adhesives, gels, polyols, starches, gums, flavorants, seasonings, salts, colorants, time-release compounds, minerals, vitamins, antioxidants, prebiotics, probiotics, aroma modifiers, lipids, and combinations thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/898,788, filed Feb. 1, 2007, and is a continuation-in-part application of U.S. application Ser No. 10/842,301, filed May. 10, 2004, patented on Feb. 23, 2010, as U.S. Pat. No. 7,666,459.

US Referenced Citations (332)
Number Name Date Kind
571521 Heberline et al. Nov 1896 A
1086936 Pounder et al. Feb 1914 A
1503094 Cramer Jul 1924 A
2473773 West Jun 1949 A
2540979 Clymer et al. Feb 1951 A
2641548 Heinrich Jun 1953 A
3320130 Henry May 1967 A
3398001 Benson Aug 1968 A
3429426 Wolf et al. Feb 1969 A
3431338 Munzel Mar 1969 A
3677898 Mitsugi Jul 1972 A
3897572 Riggs et al. Jul 1975 A
3898132 Heltrick Aug 1975 A
3931885 Nahill et al. Jan 1976 A
3957974 Hata May 1976 A
3989822 Whistler Nov 1976 A
4248857 DeNeale et al. Feb 1981 A
4295567 Knudsen et al. Oct 1981 A
4314995 Hata et al. Feb 1982 A
4332790 Sozzi et al. Jun 1982 A
4338346 Brand Jul 1982 A
4399163 Brennan et al. Aug 1983 A
4403623 Mark Sep 1983 A
4411925 Brennan et al. Oct 1983 A
4423029 Rizzi Dec 1983 A
4434231 Jung Feb 1984 A
4518696 Gehrman et al. May 1985 A
4592748 Jost Jun 1986 A
4647453 Meismer Mar 1987 A
4736849 Leonard et al. Apr 1988 A
4764389 LaBarge Aug 1988 A
4767623 Conway et al. Aug 1988 A
4781939 Martin et al. Nov 1988 A
4786507 Schmidt Nov 1988 A
4797289 Reddy Jan 1989 A
4806368 Reddy Feb 1989 A
4808626 Friedman Feb 1989 A
4814193 Shenouda Mar 1989 A
4816259 Matthews et al. Mar 1989 A
4859377 Shasha et al. Aug 1989 A
4889238 Batchelor Dec 1989 A
4935247 Martila et al. Jun 1990 A
4937077 Deetz, III Jun 1990 A
5032399 Gorbach et al. Jul 1991 A
5096717 Wirth et al. Mar 1992 A
5132137 Reimann Jul 1992 A
5160745 DeLuca et al. Nov 1992 A
5171580 Imartino et al. Dec 1992 A
5176911 Tosi et al. Jan 1993 A
5286495 Batich et al. Feb 1994 A
5292657 Rutherford Mar 1994 A
5296233 Batista et al. Mar 1994 A
5322686 Grahn et al. Jun 1994 A
5344824 Ohkuma Sep 1994 A
5389389 Beck Feb 1995 A
5413960 Dobrogosz et al. May 1995 A
5445828 Pozzi et al. Aug 1995 A
5451400 Stern et al. Sep 1995 A
5474932 Bengmark et al. Dec 1995 A
5484721 Ors et al. Jan 1996 A
5501857 Zimmer Mar 1996 A
5501868 Collings Mar 1996 A
5516684 Saito et al. May 1996 A
5518733 Lamothe et al. May 1996 A
5531988 Paul Jul 1996 A
5538743 Heinemann et al. Jul 1996 A
5540945 Ikushima Jul 1996 A
5569634 Miller et al. Oct 1996 A
5578302 Brassart et al. Nov 1996 A
5582643 Takei et al. Dec 1996 A
5603930 Brassart Feb 1997 A
5629017 Pozzi et al. May 1997 A
5633012 Ford May 1997 A
5645830 Reid Jul 1997 A
5698437 Matsuda et al. Dec 1997 A
5726161 Whistler Mar 1998 A
5728380 Allen et al. Mar 1998 A
5733540 Lee Mar 1998 A
5756088 Matsuura et al. May 1998 A
5766520 Bronshtein Jun 1998 A
5785990 Langrehr Jul 1998 A
5814338 Veronesi Sep 1998 A
5824779 Koegel et al. Oct 1998 A
5849327 Berliner et al. Dec 1998 A
5853697 Strober et al. Dec 1998 A
5854067 Newgard et al. Dec 1998 A
5858356 Wolf et al. Jan 1999 A
5871794 Brito Feb 1999 A
5871802 Gao Feb 1999 A
5894029 Brown et al. Apr 1999 A
5910447 Lawrence et al. Jun 1999 A
5939117 Chen Aug 1999 A
5952021 Santus Sep 1999 A
5952033 Anantharaman et al. Sep 1999 A
5962043 Jones Oct 1999 A
5968569 Cavadini et al. Oct 1999 A
5976579 McLean Nov 1999 A
6007808 DeHaen et al. Dec 1999 A
6010725 Meister et al. Jan 2000 A
6033888 Batich et al. Mar 2000 A
6042857 Jones et al. Mar 2000 A
6063414 Jones et al. May 2000 A
6077530 Weinstein et al. Jun 2000 A
6080401 Reddy et al. Jun 2000 A
6083520 Toneby Jul 2000 A
6117477 Paluch et al. Sep 2000 A
6133323 Hayek Oct 2000 A
6156355 Shields et al. Dec 2000 A
6190591 van Lengerich Feb 2001 B1
6254886 Fusca et al. Jul 2001 B1
6277370 Vavaliere Ved. Vesely et al. Aug 2001 B1
6309666 Hatano et al. Oct 2001 B1
6310090 Hayek Oct 2001 B1
6355242 Allison et al. Mar 2002 B1
6358555 Takahashi Mar 2002 B1
6365148 Kim et al. Apr 2002 B1
6375956 Hermelin et al. Apr 2002 B1
6394803 Salz et al. May 2002 B1
6406853 Spindler Jun 2002 B1
6451341 Slaga et al. Sep 2002 B1
6500463 van Lengerich Dec 2002 B1
6506389 Leer et al. Jan 2003 B2
6544568 La Droitte et al. Apr 2003 B2
6586027 Axelrod Jul 2003 B2
6588180 Heath Jul 2003 B2
6592863 Fuchs et al. Jul 2003 B2
6596946 Yagi et al. Jul 2003 B2
6607905 Luquet Aug 2003 B1
6620440 Hsia Sep 2003 B1
6624162 Uchida et al. Sep 2003 B2
6681935 Lewis Jan 2004 B1
6713083 McGregor et al. Mar 2004 B1
6723358 van Lengerich Apr 2004 B1
6737089 Wadsworth May 2004 B2
6746672 O'Sullivan Jun 2004 B2
6767573 Dixon et al. Jul 2004 B1
6780433 Cochran et al. Aug 2004 B2
6797266 Naidu Sep 2004 B2
6802422 Kalvelage et al. Oct 2004 B2
6827957 Paluch et al. Dec 2004 B2
6835397 Lee et al. Dec 2004 B2
6893662 Dittmar et al. May 2005 B2
6905679 Schiffrin et al. Jun 2005 B1
6911217 Gren et al. Jun 2005 B1
6932990 Konishi Aug 2005 B2
6939560 Shen et al. Sep 2005 B2
6974594 Ko et al. Dec 2005 B2
6979675 Tidmarsh Dec 2005 B2
6991819 Pannevis et al. Jan 2006 B2
7008648 Corley et al. Mar 2006 B2
7037708 Runge et al. May 2006 B1
7081478 Hauptmann et al. Jul 2006 B2
7097831 Bengs Aug 2006 B1
7115297 Stillman et al. Oct 2006 B2
7122370 Porubcan Oct 2006 B2
RE39436 Spindler et al. Dec 2006 E
7150986 Kato et al. Dec 2006 B2
7179460 Dennin et al. Feb 2007 B2
7186545 Collins et al. Mar 2007 B2
7189390 Zink et al. Mar 2007 B2
7195906 Collins et al. Mar 2007 B2
7201923 van Lengerich et al. Apr 2007 B1
7229818 Porubcan Jun 2007 B2
7235276 Allen et al. Jun 2007 B2
7235395 Stadler et al. Jun 2007 B2
7381406 Zink et al. Jun 2008 B2
7390519 Collins et al. Jun 2008 B2
7427398 Baillon et al. Sep 2008 B2
7498162 Germond et al. Mar 2009 B2
7544497 Sinclair et al. Jun 2009 B2
7547527 Baur et al. Jun 2009 B2
7550285 Schiffrin et al. Jun 2009 B2
7579030 Domingues et al. Aug 2009 B2
7647098 Prichep Jan 2010 B2
7674808 Bueno Calderon et al. Mar 2010 B2
7687077 Khoo Mar 2010 B2
7687085 Hayashi et al. Mar 2010 B2
7700141 Baillon et al. Apr 2010 B2
7700315 Arigoni et al. Apr 2010 B2
7771982 Zink et al. Aug 2010 B2
7785635 Boileau et al. Aug 2010 B1
7833554 Piccirilli et al. Nov 2010 B2
7838057 Schmidt et al. Nov 2010 B2
7842329 Saylock et al. Nov 2010 B2
7906112 Boileau et al. Mar 2011 B2
7910144 Ballevre et al. Mar 2011 B2
7935334 Lin May 2011 B2
7960605 Zhao-Wilson Jun 2011 B2
7998473 Boileau et al. Aug 2011 B2
8030279 Joullie Oct 2011 B2
8034601 Boileau et al. Oct 2011 B2
8057840 Harrison et al. Nov 2011 B2
8092608 Rochat et al. Jan 2012 B2
8101170 Plail et al. Jan 2012 B2
8142810 Sunvold Mar 2012 B2
8263146 Bengtsson et al. Sep 2012 B2
8313757 Van Lengerich Nov 2012 B2
8329190 Vidal et al. Dec 2012 B2
8394370 Garcia Mar 2013 B2
8486389 Sidhu et al. Jul 2013 B2
8524304 Prakash et al. Sep 2013 B2
8540980 London et al. Sep 2013 B2
8557764 Newell et al. Oct 2013 B2
8563522 Pitha et al. Oct 2013 B2
8637495 Waldron et al. Jan 2014 B2
8663729 Hayek et al. Mar 2014 B2
8691303 Sunvold et al. Apr 2014 B2
8722112 Zicker et al. May 2014 B2
8728559 Hayek et al. May 2014 B2
8771675 Zink et al. Jul 2014 B2
8802158 Boileau et al. Aug 2014 B2
8802179 Miller Aug 2014 B2
8808770 Henderson et al. Aug 2014 B2
8809035 Boileau et al. Aug 2014 B2
8865197 Tandler et al. Oct 2014 B2
8877178 Boileau et al. Nov 2014 B2
8894991 Boileau et al. Nov 2014 B2
8900569 Boileau et al. Dec 2014 B2
8916145 Mercenier et al. Dec 2014 B2
8962007 Perez et al. Feb 2015 B2
9089576 Piccirilli et al. Jul 2015 B2
9119843 Chen et al. Sep 2015 B2
9192177 Boileau et al. Nov 2015 B2
20020022019 Laulund Feb 2002 A1
20020035071 Pitha et al. Mar 2002 A1
20020119237 Hevey Aug 2002 A1
20030049240 Ballevre et al. Mar 2003 A1
20030060503 Hamilton Mar 2003 A1
20030092669 Chapnick May 2003 A1
20030104090 Levy et al. Jun 2003 A1
20030113306 Collins et al. Jun 2003 A1
20030143293 Shushunov Jul 2003 A1
20030157166 Chen Aug 2003 A1
20030170217 Collins et al. Sep 2003 A1
20030170355 Glazier et al. Sep 2003 A1
20030190314 Campbell et al. Oct 2003 A1
20030194423 Torney et al. Oct 2003 A1
20040001817 Giampapa et al. Jan 2004 A1
20040022882 Picirilli Feb 2004 A1
20040047896 Malnoe et al. Mar 2004 A1
20040161422 Ranganathan Aug 2004 A1
20040167229 Bakker-Arkema et al. Aug 2004 A1
20040228933 Chapnick Nov 2004 A1
20040234579 Finke Nov 2004 A1
20040253357 De Zarate Dec 2004 A1
20040265279 Dinan et al. Dec 2004 A1
20050013849 Lemaure Jan 2005 A1
20050074519 Bartnick et al. Apr 2005 A1
20050079244 Giffard et al. Apr 2005 A1
20050084479 Corthesy et al. Apr 2005 A1
20050100617 Malnoe et al. May 2005 A1
20050106131 Breton et al. May 2005 A1
20050112259 Qvyjt May 2005 A1
20050152884 Boileau et al. Jul 2005 A1
20050153018 Ubbink et al. Jul 2005 A1
20050164978 Chapnick et al. Jul 2005 A1
20050180961 Pecquet et al. Aug 2005 A1
20050208163 Brovelli et al. Sep 2005 A1
20050249837 Massimino et al. Nov 2005 A1
20050249841 Hayek et al. Nov 2005 A1
20050266438 Spindler Dec 2005 A1
20050281910 Schiffrin et al. Dec 2005 A1
20060002909 Takeda Jan 2006 A1
20060008511 Lin et al. Jan 2006 A1
20060070895 Khawaja Apr 2006 A1
20060088517 Kriegler Apr 2006 A1
20060099196 Breton et al. May 2006 A1
20060100162 Pitha et al. May 2006 A1
20060116330 Pitha Jun 2006 A1
20060121015 Collins et al. Jun 2006 A1
20060147962 Jones et al. Jul 2006 A1
20060165670 Berr et al. Jul 2006 A1
20060228448 Boileau et al. Oct 2006 A1
20060228459 Tribelhorn et al. Oct 2006 A1
20060263416 Brent, Jr. Nov 2006 A1
20070009577 Mankovitz Jan 2007 A1
20070031441 Collins et al. Feb 2007 A1
20070082107 Aimutis et al. Apr 2007 A1
20070098744 Knorr et al. May 2007 A1
20070116853 Krohn et al. May 2007 A1
20070122531 Considini May 2007 A1
20070123460 Chang et al. May 2007 A1
20070129428 Richelle et al. Jun 2007 A1
20070149466 Milburn et al. Jun 2007 A1
20070160589 Mattson et al. Jul 2007 A1
20070166295 Schildgen et al. Jul 2007 A1
20070178078 Khoo Aug 2007 A1
20070190171 Yamka et al. Aug 2007 A1
20070218164 Stojanovic Sep 2007 A1
20070231371 Pan et al. Oct 2007 A1
20070231414 Aoki et al. Oct 2007 A1
20070269515 Henriksen et al. Nov 2007 A1
20070269553 Le et al. Nov 2007 A1
20070280964 Knorr et al. Dec 2007 A1
20070286935 Grigorov et al. Dec 2007 A1
20080044481 Harel Feb 2008 A1
20080050354 Garault et al. Feb 2008 A1
20080050355 Vaslin Feb 2008 A1
20080053490 Clark et al. Mar 2008 A1
20080107699 Spigelman et al. May 2008 A1
20080145341 Myatt et al. Jun 2008 A1
20080214479 Pitha Sep 2008 A1
20080241226 Abeln et al. Oct 2008 A1
20080260696 Massimino et al. Oct 2008 A1
20080260866 Massimino et al. Oct 2008 A1
20080279786 Cash Nov 2008 A1
20080280274 Freisen et al. Nov 2008 A1
20080305210 Petersen Dec 2008 A1
20080311226 Yamka et al. Dec 2008 A1
20080317905 Yamka et al. Dec 2008 A1
20090252834 Hayek et al. Oct 2009 A1
20090263542 Lin et al. Oct 2009 A1
20090274796 Yamka et al. Nov 2009 A1
20090324761 Khoo et al. Dec 2009 A1
20100003369 Ter Haar et al. Jan 2010 A1
20100112003 Collins et al. May 2010 A1
20100150870 Young et al. Jun 2010 A1
20100203225 Kerr et al. Aug 2010 A1
20100233320 Sunvold et al. Sep 2010 A1
20100316769 Czarnecki-Maulden et al. Dec 2010 A1
20110117068 Lang et al. May 2011 A1
20110274676 Farmer et al. Nov 2011 A1
20120115798 Massimino et al. May 2012 A1
20120282373 Luhadiya et al. Nov 2012 A1
20120283197 Luhadiya et al. Nov 2012 A1
20130183255 Saunois et al. Jul 2013 A1
20140274920 Davenport Sep 2014 A1
20140348975 Davenport et al. Nov 2014 A1
20140348986 Beyer et al. Nov 2014 A1
20140349002 Beyer Nov 2014 A1
20150132420 Villagran et al. May 2015 A1
20150208679 Mir et al. Jul 2015 A1
Foreign Referenced Citations (84)
Number Date Country
199642145 Aug 1996 AU
199928098 Jul 1999 AU
1300538 May 1992 CA
2093287 Oct 1993 CA
2256256 Jun 2000 CA
2569249 Nov 2005 CA
3715070 Nov 1988 DE
4018392 Dec 1991 DE
10217970 Nov 2003 DE
0168112 Jan 1986 EP
0181170 May 1986 EP
0212746 Mar 1987 EP
0212747 Mar 1987 EP
0298605 Jan 1989 EP
0391416 Oct 1990 EP
0399819 Nov 1990 EP
0563934 Oct 1993 EP
0627173 Dec 1994 EP
0850569 Jul 1998 EP
1547466 Jun 2005 EP
1637041 Mar 2006 EP
1806056 Jul 2007 EP
1806057 Jul 2007 EP
2615203 Nov 1988 FR
2663198 Dec 1991 FR
1190387 May 1970 GB
1503094 Mar 1978 GB
1595054 Aug 1981 GB
2241421 Sep 1990 GB
2252228 Aug 1992 GB
S59213368 Dec 1984 JP
S6024153 Feb 1985 JP
S6297221 May 1987 JP
S62201823 Sep 1987 JP
03076561 Apr 1991 JP
H06256170 Sep 1994 JP
H08242763 Sep 1996 JP
2000191519 Jul 2000 JP
2001278781 Oct 2001 JP
2001309753 Nov 2001 JP
2007117083 Nov 2001 JP
1995378530 Aug 2003 JP
2004173675 Jun 2004 JP
2006055145 Mar 2006 JP
20020050048 Jun 2002 KR
20040024774 Mar 2004 KR
2086248 Aug 1997 RU
2123343 Dec 1998 RU
2388320 May 2010 RU
2407401 Dec 2010 RU
8808452 Nov 1988 WO
8905849 Jun 1989 WO
9001335 Feb 1990 WO
9117672 Nov 1991 WO
9302558 Feb 1993 WO
9404180 Mar 1994 WO
9421284 Sep 1994 WO
9503809 Feb 1995 WO
9507090 Mar 1995 WO
9709448 Mar 1997 WO
9716198 May 1997 WO
9720577 Jun 1997 WO
9819668 May 1998 WO
9827967 Jul 1998 WO
9854982 Dec 1998 WO
9909839 Mar 1999 WO
9930576 Jun 1999 WO
9952511 Oct 1999 WO
WO 9951108 Oct 1999 WO
0006127 Feb 2000 WO
0112164 Feb 2001 WO
0190311 Nov 2001 WO
03045356 Jun 2003 WO
03075676 Sep 2003 WO
2004074496 Sep 2004 WO
WO 2004100670 Nov 2004 WO
WO 2005115421 Apr 2005 WO
2005070232 Aug 2005 WO
2005092116 Oct 2005 WO
WO 2005105123 Nov 2005 WO
2007060539 May 2007 WO
WO 2007057439 May 2007 WO
2007126990 Nov 2007 WO
2007137808 Dec 2007 WO
Non-Patent Literature Citations (308)
Entry
Adeyemi et al, Analgesic and anti-inflammatory effects of the aqueous extract of leaves of Persea Americana Mill (lauraceae), Fitoterapia 73 (2002) 375-380.
Nordal et al, Isolation of mannoheptulose and identification of its phosphate in avocado leaves, Meddelelser fra Norsk Farmaceutisk Selskap (1955), 17, 207-13.
Wan et al, Dietary supplementation with 2-deoxy-d-glucose improves cardiovascular and neuroendocrine stress adaptation in rats; Am. J. Physiol Heart Circ. Physiol; Bearing dates of Oct. 10, 2003.
Ojewole et al, Anticonvulsant effect of Persea americana Mill (Lauraceae) (Avocado) leaf aqueous extract in mice. Phytotherapy research : PTR, (Aug. 2006) vol. 20, No. 8, pp. 696-700.
Appelboom, Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scandinavian journal of rheumatology, (2001) vol. 30, No. 4, pp. 242-247.
Adeyemi et al, “Analgesic and Anti-Inflammatory Effects of the Aqueous Extract Leaves of Persea Americana Mill (Lauraceae)” Fitoterapia, IDB Holding, Milan, IT, vol. 73, No. 5, Aug. 1, 2002, pp. 375-380, XP002318086.
“Avocado sugars are effective inducer of cutaneous defensive functions” Journal of the American Academy of Dermatology, C V Mosby, St Louis MO, US, vol. 50, No. 2, Feb. 1, 2007 p. AB84, XP005937005.
Burger et al., “Cardiomyopathy in Ostriches (Struthio Camelus) Due to Avocado 9Persea americana Var. guatemalensis) Intoxication”, Journal of the South African Veterinary Association, vol. Jaargang 65 No. 2, Jun./Jun. 1994.
Byung Pal Yu et al., “Modulation of Aging Processes by Dietary Restriction”, CRC Press, Boca Raton (1994).
Cullen et al. , “Inhibition of glucose metabolism in pancreatic cancer induces cytotoxicity via metabolic oxidative stress” Gastroenterology, vol. 128, No. 4 supp. 2, Apr. 2005 pp. A483, XP002495963.
Database Embase (Online) Elsevier Science Publishers, Amsterdam, NL, Nov. 2004, Carranza J et al, “Lower quantities of avocado as daily source of monounsaturated fats: Effect on serum and membrane lipids, endothelial function, platelet aggregation and C-reactive protein in patients with metabolic syndrome” XP002485347.
Ekor et al., “Protective effect of the methanolic leaf extract of Persea anericana (avocado) against paracetamol-induced acute hepatotoxicity in rats” International Jornal of Pharmacology, Asian Network for Scientific Information, vol. 2, No. 4, Jan. 1, 2006, pp. 416-420, XP001538905.
F. B. La Forge, Absorption and Effect of Ingested Mannoheptulose, Nutrition Reviews, vol. 27, No. 7 1969.
Facchini et al., Insulin Resistance as a Predictor of Age-Related Diseases, The Journal of Clinical Endocrinology & Metabolism, 86(8): 3574-3578 , 2001.
Francesconi et al., “5-Thio-D-Glucose: Hypothermic Responses in Mice”, Am. J. Physiology, 239(3) R214-R218, 1980.
Guo et al. , “In Vivo 2-Deoxyglucose Administration Preserves Glucose and Glutamate Transport and Mitochondrial Function in Cortical Synaptic Terminals After Exposure to Amyloid Beta-Peptide and Iron: Evidence for a Stress Response” Experimental Neurology, Academic Press, vol. 166. No. 1, Jan. 1, 2000, XP008056810 pp. 173-179.
Kalant et al., “Effect of Diet Restriction on Glucose Metabolism and Insulin Responsiveness in Aging Rats”, Mechanisms of Ageing and Development, 46 (1988) 89-104.
Kealy et al., “Effects of Diet Restriction on Life Span and Age-Related Changes in Dogs”, JAVMA, vol. 220, No. 9, May 1, 2002.
Koizumi et al., “Influences of Dietary Restriction and Age on Liver Enzyme Activities and Lipid Peroxidation in Mice” 1987 American Institute of Nutrition, Jul. 1986.
Kurata et al., “Structural Evaluation of Glucose Analogues on Feeding Elicitation in Rat”, Metabolism, vol. 38, No. 1 (Jan.), 1989: pp. 46-51.
Lane et al., “2-Deoxy-D-Glucose Feeding in Rats Mimics Physiologic Effects of Calorie Restriction”, Journal of Anti-Aging Medicine, vol. 1, No. 4, 1998.
Lane et al., “Calorie Restriction in Nonhuman Primates: Implications for Age-Related Disease Risk”, Journal of Anti-Aging Medicine, vol. 1, No. 4, 1998.
Lane et al., “Calorie Restriction Lowers Body Temperature in Rhesus Monkeys, Consistent With a Postulated Anti-Aging Mechanism in Rodents”, Proc. Natl. Acad. Sci., vol. 93 pp. 4159-4164, Apr. 1996.
Lawrence Fishbein et al., Biological Effects of Dietary Restriction, Springer-Verlag, 1991.
Liu et al., “‘Hass’ Avocado Carbohydrate Fluctuations. I. Growth and Phenology”, J. Amer. Soc. Hort. Sci. 124(6): 671-675. 1999.
Liu et al., “‘Hass’ Avocado Carbohydrate Fluctuations. II. Fruit Growth and Ripening”, J. Amer. Soc. Hort. Sci., 124(6): 676-681. 1999.
Liu et al., “Postulated Physiological Roles of the Seven-Carbon Sugars, Mannoheptulose, and Perseitol in Avocado”, J. Amer. Soc. Hort. Sci., 127 (1): 108-114, 2002.
Masoro et al., “Dietary Restriction Alters Characteristics of Glucose Fuel Use”, Journal of Geronotology, Biological Sciences 1992, vol. 47, No. 6 B202-B208.
McKay et al., “The Effect of Retarded Growth Upon the Length of Life Span and Upon the Ultimate Body Size”, J. Nutr., vol. 10, pp. 63-79 (1935).
Meyer et al., “Effects of D-mannoheptulose and Its Hexaacetate Ester on Hormonal Secretion From the Perfused Pancreas”, International Journal of Molecular Medicine, 6: 143-152, 2000.
Naveh et al., “Defatted Avocado Pulp Reduces Body Weight and Total Hepatic Fat but Increases Plasma Cholesterol in Male Rats Fed Diets wWth Cholesterol”, American Society for Nutritional Sciences, 2002, pp. 2015-2018.
Nutrigenomics New Zealand Sutton et al, “Considerations for successful development and launch of personalized nutrigenomic foods” Mutation Research, Amsterdam, NL, vol. 622. No. 1-2, Aug. 8, 2007, pp. 117-121, XP022191854.
Poehlman et al., “Caloric Restriction Mimetics: Physical Activity and Body Composition Changes”, Journals of Geronotology: Series A 2001, vol. 56A (Special Issue I): 45-54.
Ramsey et al., “Dietary Restriction and Aging in Rehesus Monkeys: The University of Wisconsin Study”, Experimental Gerontology, 35 (2000) 1131-1149.
Rezek et al., “Glucose Antimetabolites and Hunger”, 106: 143-157, 1975.
Roth et al., “Caloric Restriction in Primates and Relevance to Humans”, Laboratory of Neurosciences, Geronotology Research Center, National Institute on Aging, National Institutes of Health Pages, 307-315, 2001.
Scarbrough et al. “2-deoxy-D-glucose and 17-(allylamino)-17-demethoxygeldanamycin enhances toxicity as well as increases parameters indicative od oxidative stress” Free Radical Biology and Medicine, Elsevier Science, vol. 43, No. suppl. 1, Nov. 14, 2007, p. S59, XP009105389.
Sener et al., “D-mannoheptulose Uptake and Its Metabolic and Secretory Effects in Human Pancreatic Islets”, International Journal of Molecular Medicine, 6: 617-620, 2000.
Shaw et al., “High Performance Liquid Chromatographic Analysis of d-manno-Heptulose, Perseitol, Glucose, and Fructose in Avocado Cultivars”, J. Agric. Food Chem. 1980, 28, 379-382.
Simons et al. “2-deoxy-D-gulcose (2DG) enhances cispalatin cytotoxicity in human head and neck cancer cells via metabolic oxidative stress” Free Radical Biology and Medicine, vol. 41, No. suppl. 1, Nov. 15, 2006, pp. S112-S-113, XP009105143.
Sakata et al., “Feeding Modulation by Pentose and Hexose Analogues1-3”, Am. J. Clin Nutr 1992: 55:272S-7S.
Viktora, et al., “Effect of Ingested Mannopheptulose in Animals and Man”, Metabolism, 1969, vol. 18, No. 2, pp. 87-102.
Weindruch et al., “The Retardation of Aging and Disease by Dietary Restriction”, Charles S. Thomas (1988).
International Search Report received in connection with PCT/IB2008/050382, mailed on Oct. 7, 2008.
A. Nordal, et al., “Isolation of Mannoheptulose and Identification of its Phosphate in Avocado Leaves”, J. Am. Chem. Soc., vol. 76, No. 20, pp. 5054-5055, 1954.
Ridker et al., “C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-up of 14,719 Initially Healthy American Women”, Circulation, vol. 107, No. 3, pp. 391-397, Jan. 2003.
Roe et al., “The Utilization of D-mannoheptulose (d-manno-ketoheptose) by Adult Rabbits”, Biol. Chem., vol. 112, pp. 443-449, 1936.
Blatherwick et al., “Metabolism of D-mannoheptulose. Excretion of the Sugar After Eating Avocado”, J. Biol. Chem., vol. 133, pp. 643-650, 1940.
Koh et al., “Effects of Mannoheptulose on Lipid Metabolism of Rats”, J. Nutr., vol. 104, pp. 1227-1233, 1974.
Issekutz, Jr. et al., “Effect of Mannoheptulose on Glucose Kinetics in Normal and Glucocorticoid Treated Dogs”, Life Sciences, vol. 16, pp. 635-643, 1977.
Archived pages from HTTP://web.archive.org for http://medtechnologies.com dated Jan. 2003.
Archived pages from HTTP://web.archive.org for http://medtechnologies.com dated Feb. 2003.
Blue Buffalo Life Protection Formula—package.pdf, http//www.bluebuff.com/products/dogs/lp-adult-chick.shtml Information accessed Feb. 3, 2009.
Breeders Choice, AvoDERM product brochures http://www.breeders-choice.com/about/brochures.htm, Information accessed Feb. 3, 2009.
Natures Logic Natural Chicken Dinner Fare FROZEN—package.pdf http://www.natureslogic.com/products/dp—rf—chi.html, Information accessed Feb. 3, 2009.
Natures Logic Natural Chicken Meal—package.pdf http://www.natureslogic.com/products/dp—dry—chi.html, Information accessed Feb. 3, 2009.
Publication downloaded from http://en.wikipedia.org/wiki/Noni on May 4, 2009, 9 pages.
Ashcroft, et al., “Glucose Metabolism in Mouse Pancreatic Islets”, Biochem. J. (1970), 118, pp. 143-154.
Au, et al., “Avocado Soybean Unsaponifiables (ASU) suppress TNF-a, IL-lb, cox-2, iNOS Gene Expression, and Prostaglanding E2 and Nitric Ocide Production in Articular Chondrocytes and Monocyte/Macrophages”, Osteoarthritis and Cartilage, 2007, 15, 18 pages.
Balkau, et al., Diabetes Obes. Metab., 1 (Suppl. 1), pp. S23-31, 1999.
Barge, “Avocados May Help Prevent Oral Cancer, OSU Study Shows”, Journal of Dental Hygiene, vol. 82, No. 2, Apr. 2008, 3 pp.
Board, et al., “High KM Glucose Phosphorylating (Glucokinase) Activities in a Range of Tumor Cell Lines and Inhibition of Rates of Tumor Growth by the Specific Enzyme Inhibitor Mannoheptulose”, Cancer Research, vol. 55, pp. 3278-3285, Aug. 1995.
Brai, et al., “Hypoglycemic and Hypochloesterolemic Potential of Persea Americana Leaf Extracts”, J. Med. Food, 2007, pp. 356-360.
Brown, et al., “Glucose Phosphorylation is Essential for the Turnover of Neutral Lipid and the Second Stage Assembly of Triacylglycerol-Rich ApoB-Containing Lipoproteins in Primary Hepatocyte Cultures”, American Heart Association, Inc., 1999, pp. 321-329.
Chan, et al., “Ultra Structural and Secretory Heterogeneity of fa/fa (Zucker) Rat Islets”, Molecular and Cellular Endocrinology, 136, 1998, pp. 119-129.
Conde, et al., “OeMST2 Encodes a monosaccharid Transporter Expressed throughout Olive Fruit Maturation”, Plant Cell Physiol, 48(9), pp. 1299-1308, 2007.
Ernst, “Avocado-Soybean Unsaponifiables (ASU) for Osteoarthritis-A systemic Review”, Clin. Rheumatol., 2003, 22, pp. 285-288.
Frech, et al., “The Utility of Nutraceuticals in teh Treatment of Osteoarthritis”, Current Rheumatology Reports, 2007, 9, pp. 25-30.
Gallagher, et al., “The Effects of Traditional Antidiabetic Plants on In Vitro Glucose Diffusion”, Nutrition Research, 23 (2003), pp. 413-424.
Gondwe, “Effects of Oersea Americana Mill (Lauraceae) Ethanolic Leaf Extract on Blood Glucose and Kidney Function in Streptozotocin-Induced Diabetic Rats and on Kidney Cell Lines of the Proximal (LLC-PK1) and Distal Tubules (MDBK)”, Methods Find Exp Clin. Pharmacol., 2008, 30(1), pp. 25-35.
Henrotin, et al., “Pharmaceutical and Nutraceutical Management of Canine Osteoarthritis: Present and Future Perspectives”, The Veterinary Journal, 170 (2005), pp. 113-123.
Johnson, et al., “Glucose-Dependent Modulation in Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator”, Diabetes, vol. 56, Jun. 2007, pp. 1694-1702.
Kappler-Tanudyaya, et al., “Combination of Biotransformation and Chromatography for the Isolation and Purification of Mannoheptulose”, Biotechnology J. 2007, 2, 692-699.
Katzmarzyk, “The Metabolic Syndrome: An Introduction”, Appl. Physiol. Nutr. Metab., 32, pp. 1-3 (2007).
Kibenge, et al., “Identification of Biochemical Defects in Pancreatic Islets of fa/fa Rats”, Obesity Research, 3(2), pp. 171-178, Mar. 1995.
Klain, et al., “Mannoheptulose and Fatty Acid Synthesis in the Rat”, The Joumal of Nutrition, pp. 473-477, 1974.
Langhans, et al., “Changes in Food Intake and Meal Patterns Following Injection of D-Mannoheptulose in Rats”, Behavioral and Neural Biology, 38, pp. 269-286 (1983).
Maklashina, et al., “Is Defective Electron Transport at the Hub of Aging”, Aging Cell, vol. 3, 21-27, 2004.
Mermelstein, Food Technology, 51(10), p. 96, 1997.
Pelicano, et al., “Glycolysis Inhibition for Anticancer Treatment”, Oncogene, 2006, 25, pp. 4633-4646.
Rezek, J. Nutr. 106:143-157, 1972.
Rezek, et al., “Insulin Dependence of Paradoxical Overeating: Effect of Mannoheptulose, Somatostatin, and cycloheximide”, The American Physiological Society, 1979, E205-E211.
Robey, et al., “Akt, Hexokinase, mTOR: Targeting Cellular Energy Metabloism for Cancer Therapy”, Drug Discovery Today: Disease Mechanisms, vol. 2, No. 2, 2005, pp. 239-246.
Roth, Ann. Ny Acad. Aci., 928: 305-315, 2001.
Scruel, et al., “Interference of D-Mannoheptuloase with D-Glucose phosphorylation, Metabolism, and Functional Effects: Comparison between Liver, Parotid Cells and Pancreatic Islets”, Molecular and Cellular Biochemistry, 187, pp. 113-120, 1998.
Sener, et al., “Environmental Modulation of D-Fructose Insulinotropic Action”, Acta Diabetol, 1998, 35, pp. 74-76.
Shimada, “Significance of 1,5-Anhydro-D-Glucitol in Diabetes Mellitus Management”, Sangyo Igaku, 1994, 36(3), pp. 148-449.
Simon, et al., “Insulin and Proinsulin Secretion and Action”, Israel J. Med. Sci., vol. 8, No. 6, Jun. 1972.
Walker-Bone, et al., “Natural Remedies in the Treatment of Osteoarthritis”, Drugs and Aging, 2003, 20(7), pp. 517-526.
Wamelink, et al., “Detection of Transaldolase Deficiency by Quantification of Novel Seven-Carbon Chain carbohydrate Biomarkers in Urine”, J. Inherit Metab Dis, (2007), 30, pp. 735-742.
Winnock, et al., “Correlation Between Gaba Release from Rat Islet beta-cells and their Metabolic State”, Am. J. Physiol Endocrinol. Metab., 282: E937-E942, 2002.
Wood, et al., “Evidence for Insulin Involvement in Arginine- and Glucose-Induced Hypercalciuria in Rat”, J. Nutr., 113, pp. 1561-1567, 1983.
Zhang, et al., “Dissimilar Effects of D-Mannoheptulose on the phosphorylation of alpha vs beta-D-glucose by either Hexokinase or Glucokinase”, International Journal of Molecular Medicine, 14, pp. 107-112, 2004.
Andus, et al., “Imbalance of the Interleikin 1 System in Colonic Mucosa-Association with Intestinal Inflammation and Interleukin 1 Receptor Agonist Genotype 2”, Gut, vol. 31, 1997, pp. 651-657.
Anonymous, “The Best Ever Guacamole—Again, Whole Foods Market”, Jan. 18, 2013, Retrieved from the Internet: URL:http://www.wholefoodsmarket.com/blog/best-ever-guacamole-again, p. 3.
Apgar, et al., “Effect of feeding Various Levels of Bifidobacterium globosum A on the Performance, Gastrointestinal Measurements and Immunity of Weanling Pigs and on the Pelfromance and Carcass Measurements of Gorwing-Finishing Pigs”, J. Animal Science, 1993, vol. 71, pp. 2173-2179.
Aranda, et al., “Analysis of Intestinal Lymphocytes in Mouse Colitis Medicated by Transfer of CD4+, CD45RB High T Cells in SCID Recipients”, 1997, The American Assoc. of Immunologists.
Arany, et al., “The Effect of Carcinogens and Non-Carcinogens on Some Biochemical Features of the Mouse Lung Tissue”, Arch. Toxicol., Suppl. 4, 73 (1980).
Asahara, et al., “Antimicrobial Activity of Intraurethrally Adminstered Probiotic Lactobacillus casei in a Murine Model of Escherichia coliUrinary Tract Infection”, Antimicrobial Agents & Chemotherapy, 2001, 45(6): 1751-1760.
Barbara, et al., “A Role for Inflammation in Irritable Bowel Syndrome”, Gut, 2002, 51 (Suppl I), pp. i41-i44.
Begbie, et al., “The Isolation of Some Heptoses, Heptuloses, Octuloses and Nonuloses from Pimula Officinalis JACQ”, Carbohydrate Research, 1966, vol. 2, pp. 272-288.
Benno, et al., “Individual and Seasonal Variations in the Composition of Fecal Microflora of Beagle Dogs”, Bifidobacteria Microflora, vol. 11, No. 2, pp. 69-76, 1992.
Biavati, et al., “Electrophoretic Patterns of Proteins in the Genus Bifidobacterium and Proposal of Four New Species”, Journal Int. J. Syst. Bacteriol., vol. 32, pp. 358-373, 1982.
Bodmeier, “Capsule with Controlled Active Ingredient Release Comprises Active Ingredient Containing Filling, 2, Capsule Shell, Swelling Agent and Water-Insoluble Layer”, BODM, May 18, 1999.
Botterweck, et al., “Intake of Butylated Hydroxyanisole and Butylated Hydroxytoluene and Stomach Cancer Risk: Results from Analyses in the Netherlands Cohort Study”, Food and Chemical Toxicology, 38 (2000, 599-605.
Bouhnik, et al., “Effects of Bifidobacterium SP Fermented Milk Ingested with or without Inulin on Colonic Bifidobacteria and Enzymatic Activities in Healthy Humans”, European Journal of Clinical Nutrition, 1996, 50, pp. 269-273.
Brandtzaeg, et al., “Immunopathology of Human Inflammatory Bowel Disease”, Springer Seminars in Immunopathology, 1997, 18, pp, 555-589.
Bridigidi, et al., “Specific Detection of Bifidobacterium Strains in a Pharmaceutical Probiotic Product and in Human Feces by Polymerase Chain Reaction”, System Appl. Microbiol., 23, 2000, 391-399.
Campieri, et al., “Reduction of Oxaluria after an Oral Course of Lactic Acid bacteria at High Concentration”, Kidney International (2001) vol. 60, pp. 1097-1105.
Chadwick, et al., “Activation of the Mucosal Immune System in Irritable Bowel Syndrome”, Gastroenterology, 2002, 122, pp. 1778-1783.
Charteris, et al., “Antibiotic Susceptibility of Potentially Probiotic Bifidobacterium Isolates from the Human Gastrointestinal Tract”, Letters in Applied Microbiology, 1998, vol. 26, pp. 333-337.
Charteris, et al., “Development and Application of an in Vitro Methodology to Determine the Transit Tolerance of Potentially Probiotic Lactobacillus and Bifidobacterium Species in the Upper Human Gastrointestinal Tract”, Journal of Applied Microbiology, 1998, vol. 84, pp. 759-768.
Charteris, et al., “Effect of Conjugated Bile Salts on Antibiotic Susceptibility of Bile Salt-Tolerant Lactobacillus and Bifidobacterium Isolates”, Journal of Food Protection, vol. 63, No. 10, 2000, pp. 1369-1376.
Charteris, et al., “Selective Detection, Enumeration and Identification of Potentially Probiotic Lactobacillus and Bifidobacterium Species in Mixed Bacterial Populations”, International Journal of Food Microbiology, 35, 1997, pp. 1-27.
Chauviere, et al., “Adhesion of Human Lactobacillus Acidophilus Strain LB to Human Enterocyte-like Caco-2 Cells”, Journal of General Microbiology, 1992, vol. 138, pp. 1689-1696.
Chen, et al., “Action of 5-Thio-D-Glucose and Its 1-Phosphate with Hexokinase and Phosphoglucomutase”, Arch. Biochem. Biophys. 169, pp. 392-396 (1975).
Chevalier, et al., “Detection of Bifidobacterium Species by Enzymatic Methods”, Journal of Applied Bacteriology, 1990, vol. 68, pp. 619-624.
Chiricolo, et al., “Cell Adhesion Molecules CD11a and CD18 in Blood Monocytes in Old Age and the consequences for Immunological Dysfunction”, Gerontology, 1995, 41(4), pp. 227-234.
Cicco, et al., “Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor-Alpha”, The American Society of Hematology, Blood, vol. 75, No. 10, May 15, 1990, pp. 2049-2052.
Collins, et al., “A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity”, Microbial Ecology in Health and Disease, vol. 14, No. 2, Jun. 2002, pp. 81-89.
Collins, et al., “Selection of Probiotic Strains for Human Applications”, Dairy Journal, 8, 1998, 487-490.
Cooke, et al., “Role of Estrogens in Adipocyte Development and Function”, Exp. Biol. Med., 229:1127-35, 2004.
Mane, et al., “The Non-Competitive Inhibition of Brain Hexokinase by Glucose-6-Phosphate and Related compounds”, Biol. Chem., 210, pp. 597-696 (1954).
Cruzen, et al., “Effects of Caloric Restriction on Cardiovascular Aging in Non-Human Primates and Humans”, Clin. Geriatr. Med., vol. 25(4), pp. 733-743, Nov. 2009.
De Pergola, “The Adipose Tissue Metabolism: Role of Testosterone and Dehydroepiandrosterone”, Int. J. Obesity, 24: S59-S63, 2000.
Dent, et al., “Lactobacillus animalis JCM5670”, Database JCM Catalogue, Japan Collection of Microorganisms, 1986, XP002447035.
Donnelly, et al., “Differential Regulation of II-1 Production in Human Monocytes by IFN-y and IL-4”, The Journal of Immunology, vol. 145, pp. 569-575, No. 2, Jul. 15, 1990.
Dreau, et al., “Effects of 2-deoxy-D-glucose Adminstration on Immune Parameters in Mice”, Immunopharmacology, vol. 39, Jun. 1, 1998, pp. 201-213.
Dunne, et al., “Probiotics: From Myth to Reality, Demonstration of Functionality in Animal Models of Disease and in Human Clinical Trials”, Antonie Van Leeuwenhoek. Jul.-Nov. 1999;76(1-4):279-92.
Eisai, “Sustained-Release Solid Preparation of Zero Order Drug Releasing Profile Comprises Granules Obtainable by Coating Inner Core Containing Xanthine Deriv. Etc, with Film of Hardened Oil”, EISA, Dec. 22, 1989.
Fajans, et al., “Stimulation of Insulin Release in the Dog by a Nonmetabolizable Amino Acid. Comparison with Leucine and Arginine”, J. of Clinical Endocrinology and Metabolism, 33(1) 35-41, Jul. 1971.
Fontana, et al., “Long-term Calorie Restriction is Highly Effective in Reducing the Risk for Artherosclerosisin Humans”, PNAS, vol. 101(17), pp. 6659-6663 (2004).
Freund, “Capsule Containing Useful Enteric Bacteria-includes Hydrophobic Layer Non-fluid at Room Temp Isolating Bacteria from Membrane, to prevent Moisture Penetration”, Derwent Publ. Ltd. FREN, Aug. 5, 1986.
Gasche, et al., “IL-10 Secretion and Sensitivity in Normal Human Intestine and Infalmmatory Bowel Disease”, Journal of Clinical Immunology, vol. 20, No. 5, 2000.
Gatrell, et al., “The Effects of Chocolate and Chocolate by-product Consumption on Wild and Domestic Animals”, Chocolate in Health and Nutrition, Humana Press, 2013, pp. 135-141.
German, et al., “Glucose Sensing in Pancreatic Islet Beta Cells: The Key Role of Glucokinase and the Glycolytic Intermediates”, Proc. Nat. Acad. Sci., 90, 1781-1785 (1993).
Gibson, et al., “Dietary Modulation of the Human Gut Microflora Using Probiotics”, Journal of Nutrition, 1998, 80, suppl 2, S209-S212.
Gielkens, et al., “Effects of Hyperglycemia and Hyperinsulinemia on Satiety in Humans”, Metabolism, vol. 47, No. 3, pp. 321-324, 1998.
Van Damme, et al., “The Proportion of Th 1 Cells, Which Prevail in Gut Mucosa, is Decreased in Inflammatory Bowel Syndrome”, 2001, Blackwell Science Ltd. Clinical and Experimental Immunology, 125, pp. 383-390.
Vickers, et al., “Comparison of Fermentation of Selected Fructooligosaccharides and Other Fiber Substrates by canine Colonic Microflora”, AJVR, vol. 62, No. 4, Apr. 2001.
Voet, et al., Biochemistry, John Wiley & Sons, Inc., pp. 1044-1045.
Wein, et al., “Analyzing a Bioterror Attack on the Food Supply: The Case of Botolinum Toxin in Milk”, 2005, The National Academy of Sciences of the USA.
Weindruch, “The Retardation of Aging by Caloric Restriction”, Toxicol. Pathol., 1996, 24:742.
Willott, et al., “Aging and Presbycusis: Effects on 2-Deoxy-D-Glucose Uptake in the Mouse Auditory Brain Stem in Quiet”, Exp. Neurol., vol. 99(3), pp. 615-621.
Yaeshima, et al., “Bifidobacterium globosum, Subjective Synonym of Bifidobacterium pseudolongum, and Descrption of Bifidobacterium pseudolongum subsp. pseudolongum com nov. and Bifidobacterium psuedolongum subsp. globosum comb. nov.”, Systematic and Applied Microbiology, 1992, vol. 15(3), pp. 380-385.
Yamamoto, et al., “Changes in Behavior and Gene Expression Induced by Caloric Restriction in C57BL/6 Mice”, Physiological Genomics, vol. 39, No. 3, Sep. 8, 2009, pp. 227-235.
Yang, et al., “The Role of Voltage-Gated Calcium Channels in Pancreatic [beta]-Cell Physiology and Pathophysiology”, Endocrine Reviews, vol. 27, No. 6, Oct. 1, 2006.
Yu, “Aging and Oxidative Stress: Modulation by Dietary Restriction”, Free Radical Biology and Medicine, vol. 21, No. 5, pp. 651-668, 1996.
All Office Actions, U.S. Appl. No. 09/950,052 (now abandoned).
All Office Actions, U.S. Appl. No. 10/842,300.
All Office Actions, U.S. Appl. No. 11/313,198 (now abandoned).
All Office Actions, U.S. Appl. No. 11/313,199 (now abandoned).
All Office Actions, U.S. Appl. No. 12/012,317.
All Office Actions, U.S. Appl. No. 12/082,710.
All Office Actions, U.S. Appl. No. 12/168,400.
All Office Actions, U.S. Appl. No. 12/371,101.
All Office Actions, U.S. Appl. No. 12/371,266.
All Office Actions, U.S. Appl. No. 12/638,128.
All Office Actions, U.S. Appl. No. 12/716,533.
All Office Actions, U.S. Appl. No. 12/762,539.
All Office Actions, U.S. Appl. No. 12/939,594.
All Office Actions, U.S. Appl. No. 13/098,741.
All Office Actions, U.S. Appl. No. 13/098,756.
All Office Actions, U.S. Appl. No. 14/043,142.
Amendment in response to Nonfinal Office Action mailed Aug. 16, 2011 and issued in connection with U.S. Appl. No. 12/716,540 dated Nov. 15, 2011.
Amendment in response to Nonfinal Office Action mailed Jun. 10, 2011 and issued in connection with U.S. Appl. No. 12/638,101, Dated Sep. 2, 2011.
Amendment in response to Nonfinal Office Action mailed Jun. 7, 2011 and issued in connection with U.S. Appl. No. 12/716,518 dated Oct. 7, 2011.
Amendment in response to Nonfinal office Action mailed Jun. 9, 2011 and issued in connection with U.S. Appl. No. 12/716,562, dated Sep. 2, 2011.
Dorland's Pocket Medical Dictionary (24th ed.), W.B. Saunders Co. p. 15, 1989.
European Search Report Received in Connection with EP 04 81 5182, mailed on Jun. 13, 2008.
European Search Report Received in Connection with EP 04 81 5186, mailed on Jan. 7, 2013.
Final Office Action issued in connection with U.S. Appl. No. 12/638,101, mailed Dec. 30, 2011.
Final Office Action issued in connection with U.S. Appl. No. 12/716,518 mailed Jan. 4, 2012.
Final Office Action issued in connection with U.S. Appl. No. 12/716,540 mailed Jan. 10, 2012.
Final Office Action issued in connection with U.S. Appl. No. 12/716,562 mailed Dec. 29, 2011.
International Search Report for PCT/US2011/058861, dated Feb. 10, 2012.
International Search Report for PCT/US2012/035921, dated Jul. 10, 2012.
International Search Report for PCT/US2012/036035, dated Jul. 11, 2012.
International Search Report Received in Connection with PCT/US2004/043068, mailed on Sep. 25, 2007.
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/638,101, mailed Jun. 10, 2011.
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,540, mailed Aug. 16, 2011.
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716,562, mailed Jun. 9, 2011.
Nonfinal Office Action issued in connection with U.S. Appl. No. 12/716518 mailed Jun. 7, 2011.
Physician's Desk Reference, 1963 Edition, Medical Economics, Inc. Oradell, N.J., 1962, Product Identification Section, SEction Four, p. VIII and XI.
Supplemental Amendment in response to Nonfinal Office Action mailed Jun. 10, 201, and issued in connection with U.S. Appl. No. 12/638,101, dated Sep. 29, 2011.
LabScan XE User's Manual, Manual Version 1.2, A60-1010-862, Jan. 2003, 53 pp.
“Changing Times”, The Kiplinger Magazine, vol. 31, No. 1, Jan 1977, pp. 39-40.
“Lactobacillus animalis genes for 16S-23S intergenic spacer region, 23S ribosomal RNA, strain”, Database EMBL: JCM 5670, Jul. 9, 2004, XP002447038.
“Lactobacillus murinus genes for 16S-23S intergenic spacer regions, 23S ribosomal RNA, strain: JCM 1717”, Database EMBL, Jul. 9, 2004, XP002447039.
“Nutrient Profiles for Dog Foods”, Association of American Feed Control Officials Incorporated, pp. 110-119, 1994.
Alves-Filho, Drying Technology, 2002, vol. 20, No. 8, pp. 1541-1557, abstract.
Anand, et al., “Cytokines and Inflammatory Bowel Disease”, Tropical Gastroenterology, 1999, 20(3), pp. 97-106.
Anderson, et al., Nutrition Reviews, vol. 61, No. 5, pp. S17-S26, May 2003.
Naaz, et al., “THe Soy Isoflavone Genistein Decreases Adipose Deposition in Mice”, Endocrinology, 144 (8):3315-3320, 2003.
Novogrodsky, et al., “Lymphocyte Transformation Induced by Concanavalin A and its Reversion by methyl-alpha-D-mannopyranoside”, Biochim. Biophys. Acta, 1971, 228, 579-583.
Obaldiston, et al., “Microflora of Alimentary Tract of Cats”, American Journal of Veterinary Research, vol. 32, No. 9, Sep. 1971, pp. 1399-1405.
O'Callaghan, et al., “Differential Cytokine Response of Cells Derived from Different Lymphoid Compartments to Commensal and Pathogenic Bacteria”, Gastroenterology, Apr. 2003, vol. 124, Issue 4, Supplement 1, p. A339.
O'Mahony, et al., “Probiotic Human Bacteria: Selection of a New Strain and Evaluation in Vitro and In Vivo”, Gastroenterology, vol. 118, No. 4, Apr. 2000.
O'Mahony, et al., “Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout mice”, Aliment Pharmacol Ther., 2001, 15, pp. 1219-1225.
Panwala, et al., “A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdria, Spontaneously Develop Colitis”, The American Association of Immunologists, 1998. The Journal of Immunology, 1998, 161, pp. 5733-5744.
Park, et al., “Species Specific Oligonucleotide probes for the detection and identification of Lactobacillus isolated from mouse feces”, Journal of Applied Microbiology, 2005, vol. 99, pp. 51-57, XP002447051.
Pawelec, et al., “T Cell Immunosenescence In Vitro and In Vivo”, Exp. Gerontol, 1999, 34: 419-429.
Perlmann, et al., “Inhibition of Cytotoxicity of Lymphocytes by Concanavalin A in vitro”, Science, 1970, 168:1112-1115.
Powrie, et al., “Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in Scid Mice Reconstituted with CD45Rbhi CD4+ T Cells”, Immunity, vol. 1, pp. 553-562, Oct. 1994.
Purina, “Advancing Life Through Diet Restriction”, The Purina Pet Institute Symposium, 2002.
Raonimalala, et al., “Action of Soluble Carbohydrates from Avocado Fruit on Utilization of Calcium in the Rat”, Ann. Nutr Aliment, 34(4), 734-744, 1980.
Rastall, “Baceria in the Gut: Friends and Foes and How to Alter the Balance”, The Journal of Nutrition, Waltham Intl Science Symposium: Nature, Nurture, and the Case for Nutrition (2004), pp. 2022S-2026S.
Reid, et al., “Prevention of Urinary Tract Infection in Rats with an Indigenous Lactobacillus Casei Strain”, Infection and mmunity, 1985, 49(2), pp. 320-324.
Riquelme, et al., “Regulation of Carbohydrate Metabolism by 2,5-Anhydro-D-Mannitol”, PNAS, 80, pp. 4301-4305 (1983).
Rodtong, et al., NCBI Genbank Accession No. AF080100, NCBI Genbank (1998).
Roe, et al., “Further Studies of the Physiological Availability of Heptoses”, J. Biol. Chem., 121:37-43, 1937.
Rogler, et al., “Cytokines in Inflammatory Bowel Disease”, World Journal of Surgery, vol. 22, 1998, pp. 382-389 KP002296948.
Rowland, et al., “Physiological and Behavioral Responses to Glucoprivation in the Golden Hamster”, Physiology and Behavior, vol. 30, No. 5, May 1, 1983, pp. 747-747.
Ruscetti, et al., “Release of Colony-Stimulating Activity from Thymus-Derived Lymphocytes”, J Clin Invest. 1975;55 (3):520-527.
Sayegh, et al., “Impact of Hormone Replacement Therapy on the Body Mass and Fat Compositions of Menopausal Women: A Cross-Sectional Study”, Menopause, 6:312-315, 1999.
Scardovi, et al., “Deoxyribonucleic Acid Homology Relationships Among Species of the Genus Bifidobacterium”, Int. J. Syst. Bacteriol., vol. 21, pp. 276-294, 197.
Scardovi, “Irregular Nonsporing Gram-Positive Rods”, Genus Bifidobacterium Orla Jensen, 1924, 472.
Schmitt, et al., “The Immunostimulatory Function of IL-12 in T-Helper Cell Development and its Regulation by TGF-B, IFN-y and IL-4”, Chem. Immunet Basel Karger, 1997, vol. 68, pp. 70-85.
Scrimshaw, et al., “Interactions of Nutrition and Infection”, Am. J. Med. Sci., 1959, 237: 367-403.
Shanahan, et al., “Genes, Bacteria and T Cells: Ingredients for Inflammatory Bowel Disease”, Selected Summaries, Gastroenterology, 1998, 115, pp. 1595-1600.
Shanahan, “The Intestinal Immune System”, Physiology of the Gastrointestinal Tract, 3rd. ed., 1994.
Silva De Ruiz, et al., “Effect of Lactobacilli and Antibiotics on E. coli Urinary Infections in Mice”, Biol. Pharm. Bull., 1996, 19(1): 88-93.
Simon, et al., “Metabolism of Mannoheptulose in the Rat. I. Diabetogenic Action”, Arch. Biochem. Biophys., 69, pp. 592-601 (1957).
Simpson, et al., “Genomic Diversity and Relatedness of Bifidobacteria isolated from a Porcine Cecum”, Journal of Bacteriology, Apr. 2003, vol. 185, pp. 2571-2581.
Snow Brand Milk Products, “Enteric Capsules—comprising Core Contaiing Drug etc. AndCoating of Hardened Oil of M. Pt. Higher than Body Temp and Disintegrated by Lipase in Intestine”, SNOW, Mar. 31, 1986.
Sols, et al., “Substrate Specificity of Brain Hexokinase”, Biol. Chem. 210, pp. 581-595 (1954).
Soudeyns, et al., “The Moving Target: Mechanisms of HIV Persistance During Primary Infection”, Immunology Today, Oct. 1999.
SS Pharmaceutical KK, “Tablets Containing Double-Coated Granules-Obtained by Coating with Insol. Polymer, Enteric Polymer and/or Waces, Then Further Coating with Water or Acid-Soluble Polymer”, SSSE, Aug. 18, 1988.
Stallmach, et al., “Induction and Modulation of Gastrointestinal Inflammation”, Trends Immunology Today, Oct. 1998, vol. 19, No. 10, pp. 438-441.
Strober, et al., “Reciprocal IFN-Gamma and TFG-Beta Responses Regulate the Occurrence of Mucosal Inflammation”, Immunol. Today, Feb. 18, 1997, 2, pp. 61-64.
Sung, et al., “The Sphincter of Oddi is a Boundary for Bacterial Colonization in the Feline Biliary Tract”, Microbial Ecology in Health and Disease, 1990, vol. 3, pp. 199-207.
Sunvold, et al., “Dietary Fiber for Dogs: IV. In Vitro Fermentation of Selected Fiber Sources by Dog Fecal Inoculum and In Vivo Digestion and Metabolism of Fiber-Supplemented Diets”, J. Anim. Sci., vol. 73, 1995, 1099-1109.
Takeda Chemical Ind KK, “Dry Coated Tablet—Comprises Core Tablets Containing Enzyme Prepn in Enteric Films Within Outer Shell”, Take, May 10, 1982.
Tomomatsu, “Health Effects of Oligosaccharides”, 1994, Food Technology, 48, pp. 61-65.
Trovatelli, et al., “Presence of Bifidobacteria in the Rumen of Calves Fed Different Rations”, Appl. Environ. Microbiol., 1976, vol. 32(6), pp. 470-473.
Valente, et al., “Immunologic Function in the Elderly After Injury—The Neutrophil and Innate Immunity”, The Journal of Trauma Injury, Infection and Critical Care, vol. 67, No. 5, pp. 968-974, Nov. 2009.
Miller, et al., “2-Deoxy-D-Glucose-Induced Metabolic Stress Enhances Resistance to Listeria monocytogenes Infection in Mice”, Physiology & Behavior, vol. 65., No. 3, pp. 535-543, 1998, 1998, 535-543.
Miller, et al., “The Metabolic Stressor 2-Deoxy-D-Glucose (2-DG) Enhances LPS-Stimulated Cytokine Production in Mice”, Brain, Behavior, and Immunity, 1993, vol. 7, pp. 317-325, 1993, 317-325.
Ogawa, Journal of Japan Mibyou System Association, 2004, vol. 10, No. 1, p. 140-142 (with machine translation), 2004, 140-142.
Takayanagi, J. Nippon Med. Sch., 2003, vol. 70, No. 1, p. 71 (with machine translation), 2003, 71.
Goldrosen, et al., “Impaired Lymphocyte Blastogenic Response in Patients with Colon Adenocarcinoma: Effects of Disease and Age”, Journal of Surgical Oncology, 9:229-234, 1977.
Golkar, et al., “Apigenin Inhibits Pancreatic Cancel Cell Proliferation via Down-Regulation of the GLUT-1 Glucose Transporter”, Gastroenterology, vol. 130, No. 4, Jul. 22, 2006.
Grajales-Lagunes, et al., “Stability and Sensory Quality of Spray Dried Avocado Paste”, Drying Technology, Vo. 17, No. 1&2, 1999, pp. 317-326.
Greetham, et al., “Bacteriology of the labrador dog gut: A cultural and genotype approach”, J. Appl. Microbiol., 93:640-646, 2002.
Groux, et al., “Regulatory T Cells and Inflammatory Bowel Disease”, Viewpoint Immunology Today, Oct. 1999.
Hammarstrom, et al., “Mitogenic Leukoagglutinin from Phaseolus vulgaris Binds to a Pentasaccharide Unit in N-acetyllactosamine-type Glycoprotein Glycans”, Proc. Natl. Acad. Sci. USA, 79, 1611-1615 (1982).
Hemme, et al., “Lactobacillus murinus JCM1717”, Database JCM Catalogue, Japan Collection of Microorganisms, 1982, XP002447036.
Hershkovitz, et al., “Ethylene regulation of Avocado Ripening Differs Between Seeded and Seedless Fruit”, Postharvest Biology and Technology, vol. 56, No. 2, May 1, 2010, pp. 138-146.
Hildesheim, et al., “Simultaneous Measurement of Several Cytokines Using Small Volumes of Biospecimens”, Cancer Epidemiology, Biomarkers & Prevention, vol. IK1, pp. 1477-1484, Nov. 2002, abstract.
Hoffman, et al., “Diabetogenic Action of 5-Thio-D-glucopyranose in Rats”, Biochemistry, vol. 7, pp. 4479-4483 (1968).
Hommes, et al., “Anti- and Proinflammatory Cytokines in the Pathogenesis of Tissue Damage in Crohn's Disease”, 2000 Lippincott Williams and Wilkins, pp. 1363-1950.
Isolauri, et al., “Probiotics: A Role in the Treatment of Intestinal Infection and Inflammation?”, Gut, 2002, 50 (Suppl III), pp. iii54-iii59.
Iwasaki, et al., “Unique Functions of CD11b+, CD8a+ and Double Negative Peyer's Patch Dendritic Cells”, 2001, The American Association of Immunologists.
Jay, et al., “Metabolic Stability of 3-O-Methyl-D-Glucose in Brain and Other Tissues”, J. Neurochem., 55, pp. 989-1000 (1990).
Johnston, “Small Intestinal Bacterial Overgrowth”, The Veterinary Clinics of North America, Small Animal Practice, Mar. 1999, vol. 29, No. 2, Mar. 1999, pp. 523-550.
Kalani, et al., “Effects of Caloric Restriction and Exercise on Age-Related, Chronic Inflammation Assessed by C-Reactive Protein and Interleukin-6”, J. Gerontol. A. Bio. Sci. Med. Sci., vol. 61(3), pp. 211-217 (2006).
Kaufman, et al., “Identification and Quantification of Bifidobacterium Species Isolated from Food with Genus-Specific 16S rRNA-Targeted Probes by Colony Hybridization and PCR”, Appl. Environ. Microbiol., Apr. 1997, vol. 63, pp. 1268-1273.
Koizumi, et al., “Influences of Dietary Restriction and Age on Liver Enzyme Activities and Lipid Peroxidation in Mice”, J. Nutr., 117: 361-367, 1987.
Kok, et al. , “Specific Detection and Analysis of a Probiotic Bifidobacterium Strain in Intact Feces”, Applied and Environmental Microbiology, 1996, vol. 62, pp. 3668-3672.
Kudo, et al., “An Electron Microscopic Study on Bifidobacterium Pseudolongum SS-24 with Extracellular Material and Naked Bifidobacterium Thermophilum SS-19”, AJAS, vol. 2, No. 3, pp. 444-445, 1989.
Kyoto, “Sustains-Release Formulation which Floats in Stomach-Comprises Core of Fats and Oils, Coated with Drug Containing Layer of e.g., Agar”, KYOT, Jul. 10, 1987.
La Forge, “D-Mannoketoheptose, A New Sugar from the Avocado”, J. Biol. Chem. 28:511-22, 1917.
Lab Prod Ethiques Ethypharm, “Coated Microgranules Containing a Gastric Proton Pump Inhibitor with Two Hydrophobic Materials, Free from Alkali and any Ionic Surfactant”, Derwent Publications Ltd., Ethi., May 21, 1999.
Lakatos, “Immunology of Inflammatory Bowel Diseases”, Acta Physiological Hungarica, vol. 87 (4), pp. 355-372, 2000.
Leblond-Bourget, et al., “16S rRNA and 16S to 23S Internal Transcribed Spacer Sequence Analysis Reveal Inter- and Intraspecific Bifidobacterium Phylogeny”, International Journal of Systemic Bacteriology, vol. 6, No. 1, Jan. 1996, pp. 102-111.
Leclercq-Meyer, et al., “Effects of D-mannoheptulose and Its Hexaacetate Ester on Hormonal Secretion From The Perfused Pancreas”, International Journal of Molecular Medicine, 2000, vol. 6, pp. 143-152.
Lee, “Medicinal Plant Composition Suitable for Each Blood Type”, WPI/Thomson, vol. 2004, No. 46, Mar. 22, 2004.
Libby, “Inflammatory mechanisms: the molecular basis of inflammation and disease”, Nutr. Rev., Dec 2007, 65 (12 Pt. 2): S140-6.
Mamula, et al., Gastrointestinal Tract Infections—Chapter 11. 2004, pp. 79-89.
Marteau, et al., “Potential of Using Lactic Acid Bacteria for Therapy and Immunomudulation in Man”, FEMS Microbiology Reviews, 12, 1993, pp. 207-220.
Masoro, “Overview of Caloric Restriction and Aging”, Mech. Aging Dev., vol. 126, pp. 913-922 (2005).
Massi, et al., NCBI Genbank Accession No. AB102854, NCBI Genbank (1994).
Mattarelli, et al., “Characterization of the plasmid pVS809 from Bifidobacterium globosum”, Microbiologica, 1994, vol. 17, pp. 327-331.
Mattson, et al., “Beneficial Effects of Intermittent Fasting and Caloric Restriction on the Cardiovascular and Cerebrovascular Systems”, J. Nutr, Biol. 16, 3:129-137, 2005.
McCarthy, et al., “Double Blind Placebo Controlled Trial of Two Probiotic Strains in Interleukin”, Gastroenterology, vol. 122, No. 4, suppl., 1, pp. A389-A390, DDW Meeting Abstract, Nr. T962.
McCracken, et al., “Probiotics and the Immune System”, in G. W. Tannock (ed.), Probiotics, a critical review. Horizon Scientific Press, Norfolk, United Kingdom, 1999, p. 85-112.
McGee, et al., “A Synergistic Relationship Between TNF-alpha, IL-1B, and TGF-B1 on IL-6 Secretion by the IEC-6 Intertinal Epithelial Cell Line”, Immunology, 1995, 86, pp. 6-11.
McKay, et al., “Review Article: In Vitro Models in Inflammatory Bowel Disease”, Aliment Pharmacol. Ther., 1997, 11 (suppl. 3), pp. 70-80.
Mentula, et al., “Comparison Between Cultured Small-Intestinal and Fecal Microbiotas in Beagle Dogs”, Applied and Environmental Microbiology, Aug. 2005, vol. 71, No. 8, p. 4169-4175.
Meyer, et al., “Long-Term Caloric Restriction Ameliorates the Decline in Diastolic Function in Humans”, J. Am. College of Cardiology, vol. 47(2), pp. 398-402 (2006).
Mitsuoka, et al., “Ecology of the Bifidobacteria.”, The American Journal of Clinical Nutrition, Nov. 1977, vol. 30, pp. 1799-1810.
Mohamed, et al., “Effect of Long-Term Ovariectomy and Estrogen Replacement on the Expression of Estrogen Receptor Gene in Female Rats”, Eur. J. Endocrinol., 15, 142:307-14, 2000.
Molteleone, et al., “Manipulation of Cytokines in the Management of Patients with Inflammatory Bowel Disease”, Ann. Med, Nov. 2000, 32(8), pp. 552-560.
Morishita Jintan KK, “Capsule Preparation for Enteral Adminstration of Unsaturated Fatty Acids”, Derwent Publications Ltd, MORI, Oct. 30, 1997.
Moustafa, et al., “Effects of aging and antioxidants on glucose transport in rat adipocytes”, Gerontology, 1995, 41 (6)301-7.
“A Balanced Diet”, Waltham Book of Dog and Cat Nutrition, Ed. ATB, Edney, Chapter by A. Rainbird, pp. 57-74, Pergamon Press, Oxford, 1988.
“Kidney Stones in Adults (http://kidney.niddk.nih.gov, pp. 1-14).”, cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005.
“Mice and Rats”, (www.petswarehouse.com, pp. 1-5), cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005.
“Probiotic Basics”, (www.usprobiotics.org.basics/, p. 1-12), cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005.
“Urinary Tract Infections in Adults”, (http://kidney.niddk.nih.gov, pp. 1-11), cited by USPTO in connection with U.S. Appl. No. 11/012,570 on Dec. 12, 2005.
Arai, et al., “Cytokines: Coordinates of Immune and Inflammatory Responses”, Annu. Rev. Biochem., 1990, 59: 783-836.
Barrows, et al., “Diet and Nutrition”, Walleye Culture Manual, R. C. Summerfelt, editor, NCRAC Culture Series 101, North Central Regional Aquaculture Center Publications Office, Iowa State University, Ames, First Edition, 1996.
Collins, “Probiotics and Man—The Host Microbe Interface”, Abstracts, Gastroenterology, vol. 116, No. 4, Apr. 1999.
Favier, et al., “Fecal B-D-Galactosidase Production and Bifidobacteria are Decreased in Crohn's Disease”, Digestive Diseases and Sciences, vol. 42, No. 4, Apr. 1997, pp. 817-822.
Fujisawa, “Long-Acting Oral Prepn.—comprises Rapidly Soluble Inner Layer and Sustained Release Outer Layer, Both Layers Containing Principal Agent, which is Coronary or Peripheral Vasodilator”, FUJI, Sep. 20, 1991.
Hillsvet, “Hill's Presciption Diet, A New Way to Define Pet Obesity”, Internet Article, 2010, http://www.hillsvet.com/conference-documents/Weight—ManagementfTherapeutic?Weight—Reduction—Program/BFI—Backgrounder—pdf.
McBrearty, et al., “Probiotic Bifidobacteria and Their Identification Using Molecular Genetic Techniques”, Teagasc, Dairy Products Research Centre, Moorepark, Fermoy, Co., Cork, Ireland, Department of Microbiology, University College, Cork Ireland, In, J. Buttriss and M. Saltmarsh (ed), 2000, p. 97-107, Royal Society of Chemistry, Cambridge, United Kingdom.
Medaglini, et al., “Mucosal and Systemic Immune Responses to Recombinant Protein Expressed on the Surface of the Oral Commensal Bacterim Streptococcus gordonil after Oral Colonization”, Proc. Nat. Acad. Sci. USA, vol. 92, pp. 3868-6872, Jul. 1995, Medical Sciences.
Morishita Jintan KK, “Yogurt for Supply Physiologically Important Intestinal Bacteria—Contains Bacteria contained in Capsule Havingn Inner Layer Made of Digestible Substance and Outer Layer Dissolving in Intesting”, MORI, Mar. 10, 1995.
Murphy, et al., “Evaluation and Characterisation of Probiotic Therapy in the CD45RB Transfer Model of Colitis”, AGA Abstracts, Gastroenterology, vol. 116, No. 4, Apr. 1999.
O'Callaghan, et al., “Human Cytokine Production by Mesenteric Lymph Node Cells in Response to Probiotic and Pathogenic Bacteria”, Gastroenterology, vol. 122, No. 4, Suppl. 1., pp. A -151 DDW Meeting Abstract No. S1043, Apr. 2002, XP09036734.
O'Halloran, et al., “Adhesion of Potential Probiotic Bacteria to Human Epithelial Cell Lines”, Departments of Microbiology and Medicine, University College, Mercy Hospital, Cork, Ireland, Dept of Surgery, Mercy Hospital Cork, Ireland, 1998.
O'Mahony, et al., “Probiotic Bacteria and Pathogenic Bacteria Elicit Differential Cytokine Responses from Dendritic ells”, Gastroenterology, 120(5) 1625, Suppl., Apr. 1, 2001, Xp-001097379.
O'Mahony, et al., “Probiotic Bacteria and the Human Immune System”, Proceedings of the British Nutrition Foundation/Royal Society of Chemistry (Food Chemistry Group) “Functional Foods '99—Claims and Evidence”. BNF (London), 2000, pp. 63-70.
Schrek, et al., “Characterizatoin of the B Lymphocyte Response to Pokeweed Mitogen”, Annals of Clinical and Laboratory Science, 1982, vol. 12, Issue 6, pp. 455-462.
Stagg, et al., “The Dendritic Cell: Its Role in Intestinal Inflammation and Relationship with Gut Bacteria”, Gut, 2003: 52: 1522-1529.
Tesfay, et al., “Anti-Oxidant Levels in Various Tissues During the Maturation of ”Hass“ Avocado”, Journal of Horticultural Science and Biotechnology, (2010) 85(2): 106-112.
Seikagaku jiten (third edition), Tokyo Kagaku Dojin Publishing Co., Inc., 1998, pp. 657-658.
Related Publications (1)
Number Date Country
20080260866 A1 Oct 2008 US
Provisional Applications (1)
Number Date Country
60898788 Feb 2007 US
Continuation in Parts (1)
Number Date Country
Parent 10842301 May 2004 US
Child 12012317 US